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SUMMARY 
 
 
Malaria is recognised as one of the main health priorities by the World Health 
Organization. The most severe form of the disease, tropical malaria, is caused by 
Plasmodium falciparum. The diffusion of strains of this pathogen, resistant to traditional 
antimalarial treatments, urgently imposes the development of new therapies. P. falciparum 
belongs to the phylum Apicomplexa, which consists of unicellular, obligate intracellular 
parasites. These organisms possess an organelle of algal origin, the apicoplast, which has 
been shown to be required for pathogen survival and represents a known site of action of 
antimalarial compounds. In the apicoplast of P. falciparum a ferredoxin-NADP+ reductase 
(PfFNR) has been identified. This enzyme is directly involved in the electron transfer 
pathway from NADPH to LytB which catalyzes the last step of the mevalonate-
independent isoprenoid biosynthesis. The crystallographic structure of PfFNR in complex 
with the substrate analogue 2’-P-AMP showed the presence of two basic residues, His286 
and Lys249, in the NADP(H)-binding site, which are conserved within the Plasmodium 
genus but not in other plant-type homologues.  
Aim of this work has been to clarify the role of His286 and Lys249 in substrate binding 
and catalysis, and to identify and characterize PfFNR inhibitors.  
The study of His286 and Lys249 was carried out by site-directed mutagenesis. The 
replacement of His286 resulted in a multifaceted effect, which highly depended on the 
replacement made. Steady-state kinetics showed that the substitution with aliphatic 
residues, i.e. Ala and Leu, decreases both kcat/KmNADPH and kcat indicating that His286 plays 
a critical role not only in NADP(H) binding but also in catalysis. 2’-P-AMP inhibition 
studies and titrations with NADP+ also support this conclusions showing a decreasing in 
substrate affinity. Moreover rapid kinetic studies clearly demonstrated that the substitution 
His286Leu leads to a 3.4-fold decrease in the hydride-transfer (HT) rate between 
NADP(H) and FAD, with a destabilization of CT complexes between them. The 
His286Lys mutation resulted in the lowest kcat but surprisingly this enzyme form binds    
2’-P-AMP and NADP+ with high affinity, indicating that this mutation destabilized the 
HT-competent conformation of the substrate NADP(H). Unexpectedly, steady-state 
kinetics and stopped-flow experiments showed that the mutation to Gln gave an enzyme 
more active than the wild-type, providing a better stabilization of the HT-competent 
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conformation between nicotinamide and isoalloxazine ring. Thus, His286 has a role in 
modulating the enzyme affinity for NADP(H) and in the precise positioning of the 
nicotinamide ring in the active site. The replacement of Lys249 with an Ala resulted in an 
enzyme form with a 10-fold decrease in KmNADPH and Kd for NADP+ or 2’-P-AMP. In 
particular, as came out from the study of the NADH-K3Fe(CN)6 reductase reaction, this 
residue participates in substrate recognition by interacting with the 2’-phosphate of the 
pyridine dinucleotide. 
By the in silico screening of two virtual libraries I have identified a pool of compounds 
potentially active against PfFNR. Five compounds, i.e. I8, I19, I21, I24 and I27, showed an 
IC50 in the micromolar range and I deeply characterized their inhibition mechanism by 
steady-state kinetic studies, also evaluating their specificity. Although in the in silico 
screening the substrate-binding site of PfFNR was targeted for the selection of enzyme 
ligands, all the compounds found turned out to inhibit PfFNR by a mixed-type mechanism, 
and did not show the expected pure competitive behavior towards NADPH. Some of the 
inhibitors turned out to be very specific for Apicomplexan FNRs.  
Inhibition studies were carried out also to characterize the mechanism of ebselen, a 
compound selected within the experimental of a library of more than thousand diverse 
compounds. Steady-state kinetic studies and spectrofluorimetric analysis showed that 
ebselen is able to inhibit PfFNR with a two-phases mechanism consisting of a rapid 
enzyme inactivation followed by a slow FAD release. The inactivation process resulted to 
be irreversible without any formation of an initial reversible enzyme-inhibitor complex. 
Moreover the inactivation constant is higher at pH 8.2 rather than at pH 7 consistently with 
a covalent modification of PfFNR sulphydrylic groups. I also found that FAD release in 
PfFNR-C99A-C284S is markedly slowed down, suggesting a critical role of the active-site 
Cys284 in ebselen inhibition mechanism. Nevertheless the mild effect of mutation 
Cys284Ser on inactivation process suggests that FAD release and inactivation processes 
involve the modification of different Cys residues.  
The need of large amount of purified enzyme for in-depth functional and structural 
characterization and inhibition studies prompted us to find a new expression system for 
PfFNR, able to decrease the cost of protein purification. Thus, I developed an expression 
system for PfFNR-C99A based on the fusion with the yeast SUMO protein. The partial in 
vivo degradation of poly-His-SUMO-PfFNR-C99A prevented the obtainment of high 
expression levels. However, a procedure for the rapid and cheap isolation of the 
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recombinant protein was developed, representing an attractive alternative to the previous 
protocol. 
The features of PfFNR highlighted by the studies here reported, point out that PfFNR 
could represent an attractive drug target, suitable for the development of novel antimalarial 
compounds. 
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INTRODUCTION 
 
1.1 MALARIA 
 
In 2008 the World Health Organization estimated that malaria inflicted acute illness on 243 
million of people worldwide and led to an estimated 863.000 deaths, of which 89% were in 
the African region, followed by the Eastern Mediterranean (6%) and South-East Asia (5%) 
regions (Figure 1.1). The majority (85%) of deaths were in children under five years of 
age. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Worldwide malaria distribution. 
 
 
Four Plasmodium spp. are responsible for malaria in humans: P. vivax, P. malariae, P. 
ovale, and P. falciparum. Malaria clinical manifestations are high fever, nausea and 
general weakening. The most severe form of the disease is cerebral malaria which presents 
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loss of consciousness, changes in mental status and coma, and, if not treated, is fatal within 
24-72 hours. Cerebral malaria is caused by the infection of P. falciparum: parasitized red 
blood cells adhere to endothelial cells of brain and intestine causing blockage of the blood 
flow.  
The emergence and spread of drug-resistant parasites made urgent the development of new 
antimalarial drugs. Currently, the two most widely used antimalarial drugs, chloroquine 
and sulfadoxine/pyrimethamine, are failing at an accelerating rate in most malaria-endemic 
regions. Moreover, other antimalarial drugs, such as the artemisinine derivatives, retain 
efficacy but have limitations, one of which is their high cost. Both the development of 
compounds against previously successfull targets and the identification of new target are 
required. The sequencing of P. falciparum genome revealed that the apicoplast, a vestigial 
plastid essential to parasite survival, may be a target for the development of new drugs. 
 
 
1.2 THE PLASMODIUM PROTOZOAN 
 
The phylum Apicomplexa includes many thousands of protozoan organisms and some of 
them, such as Toxoplasma gondii, Cryptosporidium, Eimeria, Coccidia and Babesia, are 
parasites which cause important clinical and veterinary diseases. Plasmodium belongs to 
Apicomplexa and it is the obligate intracellular parasite responsible for malaria (Seeber F. 
et al., 2008). All Apicomplexa differ from each other for transmission strategy and 
symptoms of the caused disease, but they share the same subcellular architecture (Roos D. 
S. et al., 2002). Besides nucleus, mitochondrion and endoplasmic reticulum, Apicomplexa 
exhibit a distinctive ‘apical complex’ from which the phylum is named. This apical 
complex includes specialized secretory organelles (rhoptries, micronemes and dense 
granules) and cytoskeletal elements (Figure 1.2) which are involved in host cell attachment 
and invasion. In particular microneme proteins are secreted upon host cell contact, rhoptry 
contents are released concomitantly with the establishment of the intracellular 
parasitophorus vacuole, within which the replicating parasites reside (Carruthers V. B. et 
al, 1997), and dense granules are involved in the absorption of nutrients from host cell. 
Moreover the Apicomplexa possess an organelle, named apicoplast, related to non-
photosyntetic plant plastid (McFadden G. I. et al., 1999, Fleige et al., 2010).  
Four Plasmodium species infect humans: P. falciparum, P. vivax, P. ovale and P. malariae. 
Their complex life cycle involves an insect vector (Anopheles mosquito) and a vertebrate 
 10 
host (human). During a first exo-erythrocytic phase, the sporozoites reach the liver and 
invade the cells within which the asexual division starts. Then, thousands of merozoites are 
released from each liver cells and attach onto the red blood cell membrane entering them. 
Within the red blood cell, the asexual division starts giving new merozoites (erythrocytic 
phase). These merozoites are released by the lysis of the red blood cell and they 
immediately invade uninfected red cells. Some of the new merozoites in the red blood cells 
differentiate into male and female gametocytes. When Anopheles mosquito takes blood 
meal, also ingests gametocytes which continue their development in the mosquito giving 
sporozoites which reach the salivary gland (sporogonic cycle). Then mosquito during 
blood meal injects sporozoites in human blood stream and the cycle occurs again (Figure 
1.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Plasmodium falciparum structure. From Bannister L. H. et al, 2003. 
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Figure 1.3. Life cycle of Plasmodium 
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1.3 THE APICOPLAST 
 
With the exception of Cryptosporidium parvus (Abrahamsen et al. 2004), Apicomplexan 
parasites possess a non-photosynthetic organelle, called apicoplast, which has an own 
genome with a size of 35 kb encoding two large-subunit and two small-subunit of 
ribosomal RNA, a complete set of tRNAs, ribosomal proteins, three subunits of RNA 
polymerase, a protein implicated in DNA replication, the elongation factor Tu, a clp 
protease and a few additional unknown ORFs (Wilson et al., 1996, Funes et al., 2004). 
Since the apicoplast is essential for parasite survival, its exclusive metabolic pathways are 
promising targets for the development of new drugs (Fleige et al., 2010, Goodman et al., 
2007, Seeber et al., 2010).  
 
 
1.3.1 EVOLUTIONARY ORIGIN OF THE APICOPLAST  
 
More than 50 years ago, morphological studies performed by electron microscopy on 
various apicomplexans, revealed the existence of a structure surrounded by four 
membranes (McFadden et al., 1997, Siddall et al., 1992). The discovery and then the 
sequencing of a circular 35 kb-extrachromosomal DNA element of Plasmodium 
falciparum encoding an RNA polymerase with high similarity to that of prokaryotes and 
chloroplast (Gardner et al., 1991) were the first evidence for an alga-Apicomplexa 
connection. In particular the apicoplast genome analysis of Plasmodium falciparum, 
Eimeria tonella and Toxoplasma gondii strongly suggested that the apicoplast was 
originated by secondary endosymbiosis event in which an apicomplexan-like ancestor 
engulfed and retained another plastid-containing eukaryote (a photosynthetic unicellular 
alga), originated by a primary endosimbiosis between eukaryotic cell and photosynthetic 
prokaryote (Kolher et al., 1997, Obornik et al., 2009). 
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igure 4 Pictorial representation of the origin of the apicoplast 
(A) The photosynthetic cyanobacterium (green) is engulfed by a primary eukaryote (light blue) and some of the genes from the 
primary endosymbiont are transferred to the host nucleus (dark 
blue). Subsequently, this eukaryote containing the endosymbiont is engulfed further by a secondary eukaryote (buff). Here again, 
some genes are transferred to the host nucleus (red) reducing the 
apicoplast genome to the bare minimum. (B) During evolution, most of the genes were transferred from the plastid to the nucleus. 
Some of these genes code for proteins destined to the apicoplast 
(APM, apicoplast membrane). These proteins carry a signal peptide (SP; shown in pink) followed by a transit peptide (TP; shown in 
blue). The SP directs the protein into the endoplasmic reticulum 
where it is cleaved by a signal peptidase I. The resultant protein carries the TP, which directs its entry into the apicoplast. The TP is 
then cleaved by the plastid peptidase. Thus the nuclear-encodedproteins enter the apicoplast by a bipartite targeting signal. 
 
 
 
 
Figure 1.4. Evolutionary origin of the apicoplast. The photosynthetic prokaryote (green) 
is engulfed by a eukaryote (light blue) and some of the genes from the primary 
endosymbiont are transferred to the host nucleus (dark blue). Subsequently, this eukaryote 
containing the endosymbiont is engulfed further by a apicomplexan-like ancestor (pink). 
Here again, some genes are transferred to the host nucleus (red) reducing the apicoplast 
genome to the bare minimum. From Surolia et al., 2004. 
 
 
 
 
1.3.2 PROTEIN IMPORT INTO THE APICOPLAST 
 
Throughout evolution, most of the genes coding for apicoplast-resident proteins have been 
transferred to the nuclear genome being synthetized on cytoplasmic ribosomes and then 
targeted to the organelle into the secretory pathway (Roos et al., 1999, Yung et al., 2003, 
DeRocher et al., 2000). Soluble proteins are addressed to the apicoplast by a bipartite N-
terminal sequence which is composed of a signal peptide (SP, 20-30 aminoacids,) followed 
by a transit peptide (TP, 50-200 aminoacids). The SP facilitates the entry of the protein 
into the secretory pathway. Here the SP is cleaved and thereby the following TP guides the 
protein toward the apicoplast and mediates its import. (Tonkin et al., 2008, Sheiner et al., 
2008, Waller et al., 2000). Inside the apicoplast the TP is then cleaved yielding the mature 
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polypeptide. The bipartite signal was exploited to perform bioinformatic predictions from 
the complete genome data of P. falciparum, leading to the identification of more than 500 
putatively apicoplast-localized proteins. However, bioinformatic approaches provided a 
reconstruction of apicoplast metabolic pathways but only in few cases there are 
biochemical evidences supporting the bioinformatic prediction (Gardner et al., 2002, 
Zuegge et al., 2001). Probably, among these hundreds proteins only some of them are 
really localized in the apicoplast and some other have not been yet identified. The 
improvement of prediction tools based on the aminoacidic distribution on TP might help to 
identify candidate apicoplast-localized proteins (Zuegge et al., 2001, Foth et al., 2003). 
 
 
1.3.3 APICOPLAST FUNCTIONS 
 
Since the evolutionary origin of the apicoplast, most of its metabolic pathways are 
fundamentally different from the mammalian host equivalents, making them potential 
targets for drug development. Using the metabolic pathways of plant chloroplast and 
bacteria as models, it has been illustrated an extensive apicoplast metabolic networks 
reconstructed from the list of apicoplast proteins that have been predicted using 
bioinformatics (Ralph et al., 2004). It has been hypothesized that apicoplast is involved in 
the synthesis of iron-sulfur cluster, heme, fatty-acids, and isoprenoids. 
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Figure 1.5. Overview of apicoplast metabolic pathways. From Ralph et al. 2004 
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1.3.3.1  FATTY-ACIDS SYNTHESIS 
 
Fatty-acids (FA) synthesis has an important role in any living cell serving as building 
blocks of membrane lipids, for post-translational modifications of proteins etc. All the 
apicomplexan parasites have presumably an high demand for lipids and phospholipids 
since, in addition to the usual eukariotyc membrane-bound compartments (nucleus, 
endoplasmic reticulum, Golgi apparatus, mithocondria), they possess additional organelles 
such as micronemes, rhoptries, dense granules, the growing parasitophorous vacuole and 
the apicoplast (Bisanz et al, 2006). In all the Apicomplexa, enzymes of the FA synthesis 
have been found to be targeted in the apicoplast, which strong implicates that this organelle 
is the site of fatty-acids synthesis. The eukaryotic FA synthesis (type I) is carried out in 
one cytosolic multifunctional complex, the fatty-acid syntase which combines all 
enzymatic step of the synthesis. In contrast, the bacterial FA synthesis (type II) is carried 
out by distinct enzymes (Campbell et al., 2001). In the apicoplast, an isoform of ACC 
(acetyl-CoA carboxylase) it has been found. This important enzyme catalyses the 
formation of malonyl-CoA from acetyl-CoA, the starting compound of FA synthesis. 
Moreover in the apicoplast enzymes FabH, FabZ, FabI and the protein ACP (acyl carrier 
protein) have been identified (Waller et al.,1998). Recently thiolactomycin, clodinafop and 
triclosan have been reported as compounds targeting enzymes of FA type II biosynthetic 
pathway. They are active against parasites either in vivo or in vitro. Thiolactomycin has 
been reported to kill parasites acting against FabH even if its target in E. coli is FabB 
(Rock et al., 2002, Heath et al., 2002). However the structural homology between the two 
enzymes explains this double inhibition.  
Clodinafop is able to inhibit the plant-plastid ACC and it has been reported to inhibit the 
ACC of T. gondii (Jelenska et al., 2001). Triclosan is used as broad spectrum antibacterial 
in many consumer products and it has been recently shown that it inhibits FabI, the enzyme 
of P. falciparum and T. gondi which catalyses the NADH-dependent reduction of enoyl-
ACP, either in vivo or in vitro (Levy et al., 1999). 
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1.3.3.2  HEME BIOSYNTHESIS 
 
In constrast with animals where heme biosynthesis is exclusively mitochondrial 
(Heinemann et al., 2008), the pathway of heme synthesis in P. falciparum is a complex 
process involving different cellular compartments. Indeed, the initial step of the pathway is 
mithocondrial (Neuhaus et al., 2000) but prediction tools indicate that some subsequent 
reactions take place in the apicoplast. Moreover, the steps of the pathway that follow 
apicoplast involvement seem to be either/both mithocondrial or cytosolic and probably the 
pathway terminates in mitochondrion. The evolutionary history of the apicoplast made 
probably this process complex and articulate. Maybe the redundance in the heme synthesis 
pathway of mitochondrion and apicoplast, subsequent to endosymbiosis, was resolved by 
the loss of several steps from each compartment, resulting in a chimeric pathway that is 
shared between several compartments. Notably, apicoplast and mithocondrion have an 
intimate physical association during specific stages of the parasite erythrocytic life cycle 
(Hopkins et al., 1999) which could explain substrate exchange between compartments.  
Heme synthesis is an established target for herbicides (Prasad et al., 1995) and, since P. 
falciparum posseses plant-like heme synthesis enzymes, the elucidation of the entire 
pathway should provide further potential drug targets. 
 
 
1.3.3.3  ISOPRENOIDS SYNTHESIS 
 
Isoprenoids are a diverse range of compounds, composed of repeated isopentenyl 
pyrophosphate (IPP) units, and are important for organisms metabolism since participate to 
the formation of dolichols and ubiquinones, and to proteins prenylation. Two different 
metabolic pathways for the isoprenoids synthesis are known. One is the mevalonate-
dependent pathway which is typical of eukaryotic cells. The other is the DOXP-pathway 
which was previously described only for bacteria and chloroplast (Schwender et al., 1996, 
Disch et al., 1998, Clastre M. et al., 2007). In 1995 the first report of the existance, in P. 
falciparum apicoplast, of enzymes for DOXP-dependent IPP biosynthesis was published 
(Jomaa et al., 1995). In the apicoplast the isoprenoids are synthetized starting from 
pyruvate and GA3P (glyceraldehyde 3-phosphate) which are converted in DOXP (1-
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deoxy-D-xylulose-5-phosphate) by the enzyme DXS (DOXP synthase). This pathway is 
distinct from the eukaryotic biosynthesis of isoprenoids starting from mevalonate. On the 
basis of predicted apicoplast proteins, the enzymes involved in the DOXP-pathway have 
been identified in P. falciparum (Figure 1.5). After the formation of DOXP, there are six 
enzymes, called IspC/D/E/F/G/H, which provide the final products IPP and DMAP 
(dimethylallyl pyrophosphate). Even if the mechanism by which IPP is transported out of 
plastid is poorly understood, cytosolic enzymes using these compounds have been found. 
The isoprene units are used not only for protein prenylation, mithocondrial ubiquinones 
and dolichols formation, but also for the modification of tRNAs that are essential for 
apicoplast translation (Couto et al., 1999). Drugs targeting the DOXP pathway (Jomaa et 
al., 1995) might act by blocking the supply of any of the final products. Moreover given 
that the enzymes of the DOXP pathway are not found in humans, they constitute attractive 
candidate drug targets to combat the pathogens that rely on them (Singh et al., 2007). In 
human clinical trials the use of fosfidomycin, an IspC inhibitor, demonstrates that this 
pathway is a potential drug target and gives impulse to found other targets in this pathway. 
In 2005 IspH (LytB), the enzyme which catalyses the last step of DOXP-pathway (Figure 
1.6), has been proposed as new target of antimalarial drugs (Rohrich et al., 2005). 
 
 
 
 
 
 
 
 
Figure 1.6: Reaction catalyzed by IspH (LytB). HMBPP ((E)-4-hydroxy-3-methyl-but-
2-enyl diphosphate) is formed in several steps from pyruvate and glyceraldehyde 3-
phosphate and then is converted into IPP and DMAP (dimethylallyl pyrophosphate). 
 
Moreover LytB, which possesses a [4Fe-4S] cluster, was shown to directly interact with 
the NADPH-dependent electron transfer system of P. falciparum comprising a [2Fe-2S] 
ferredoxin (Fd) and ferredoxin-NADP+ reductase (FNR). These two proteins are encoded 
in the nucleus and then translocated in the apicoplast (Vollmer et al., 2001, Seeber et al., 
2005). Activity assays and mass spectrometry experiments demonstrated that the Fd/FNR 
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redox system is directly involved in a apicoplast metabolic pathway serving as an electron 
donor for LytB. 
 
 
 
1.4 FERREDOXIN-NADP+ REDUCTASE 
 
Ferredoxin-NADP+ reductase are flavoenzymes (FNR; EC 1.18.1.2) belonging to 
dehydrogenase electron-transferases and containing flavin adenine dinucleotide (FAD) as 
prosthetic group which is responsible of the catalytic properties of holoenzyme. FAD, 
derived from vitamin B2, is characterized by the presence of isoalloxazine ring which 
represents the reactive portion. The flavin can exist in three different redox states, the 
oxidized, coloured of the characteristic bright yellow (FAD), the one-electron reduced 
semiquinoid and the fully reduced (FADH2) species.  
 
 
Figure 1.7. Redox states of flavin. 
 
 
FNRs share the ability to catalyze the transfer of reducing equivalent between NADP(H) 
and ferredoxin (Fd), a protein containg Fe-S cluster, or flavodoxin (Fld), a protein 
containing FMN as prosthetic group.  
oxidized flavin λmax=450 nm λmax=560 nm 
(blue) 
semiquinone λmax=490 nm 
(red) 
reduced flavin  
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  2 Fd (Fe+2) + NADP+ + H+  2 Fd (Fe+3) + NADPH 
  2 Fld (FMNH) + NADP+ + H+  2 Fld (FMN) + NADPH 
 
 
Flavoproteins with FNR activity have been found in plant plastids, bacteria and 
mithocondria. An event of convergent evolution originated two families of flavoproteins 
which exhibit different sequences and structures but catalyse the same reaction. The first is 
the family of mithocondrial-type FNRs, known as adrenodoxin reductases (AdRs), the 
second comprises plant-type FNRs.  
 
 
1.4.1 PHOTOSYNTHETIC FNRs 
 
In plant photosynthetic tissues, FNR is associated to thylakoids membrane where catalyses 
the last step of the electron transport chain. In particular it promotes the transfer of two 
electron from ferredoxin (one-electron donor, Fd), reduced by photosystem I, to 
NADP+(two-electron acceptor)  
 
  2 Fdred + NADP+ + H+  →  2 Fdox + NADPH 
 
In 1984 Batie and Kamin formulated the first detailed pathway for the FNR-mediated 
electron transfer between ferredoxin and NADP+. The overall reaction was interpreted as 
an ordered two-substrate process, with NADP+ binding first. Moreover they demonstrated 
that the kinetics were consistent with the formation of ternary complexes as intermediates 
of the catalytic mechanism (Figure 1.8, step 2 and 5). FNR catalyses this reaction 
exploiting the capability of FAD to accept one electron from ferredoxin (one-electron 
donor) and to transfer two electron to NADP+ (two-electron acceptor) as hydride ion. 
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Figure 1.8. The electron transfer mechanism of FNR. Oxidized forms are white, one-
electron reduced forms are light grey and two-electron reduced forms rea dark grey. From 
Carrillo et al., 2003. 
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1.4.2 NON-PHOTOSYNTHETIC FNRs 
 
In 1990 an FNR has been found in a non-photosynthetic plastid (Morigasaki, 1990). This 
isoform catalyses the electron transfer in an opposite direction respect to chloroplast FNR. 
In particular non-photosynthetic FNR transfers electrons from NADPH to ferredoxin: 
 
  2 Fdox+ NADPH  →  2 Fdred + NADP+ + H+ 
 
In plant roots, reduced ferredoxin acts as electron donor for enzymes involved in nitrogen 
and sulfur assimilation. Tissues from pea root have been shown to be able to induce, in 
presence of nitrates, synthesis of a protein detected by anti- leaf FNR (lFNR) antibodies 
(Bowsher et al.,1993). Moreover an FNR from root (rFNR) it has been isolated from a 
cDNA library of root tissues genes transcribed after nitrates exposure (Aoki, 1994, Ritchie 
et al., 1994). This gene regulation is markedly different from that of photosynthetic FNRs 
which are regulated exclusively by light.  
 
 
1.4.3 FNRs TRIDIMENSIONAL STRUCTURE 
 
Today tridimensional structure of various plant-type FNRs (Karplus et al., 1991; Karplus 
et al., 1994; Deng et al., 1999; Aliverti et al., 2001), Anabaena FNR (Serre et al., 1996), E. 
coli FNR (Ingelman et al., 1997) Azotobacter vinelandii FNR (Prasad et al., 1998) are 
known. Plant-type FNR is made of two structural domains, each containing approximately 
150 amino acids. The C-terminal region, topologically similar to the supersecondary 
structure named Rossmann fold, includes most of the residues involved in NADP(H) 
binding. Plant-type FNRs are remarkably specific enzymes showing a strong preference for 
NADP(H) over NAD(H). Substrate discrimination is due to a number of charge 
interactions that FNR establishes with the 2’-phosphate group of the substrate (Carrillo et 
al., 2003, Aliverti et al., 2008). The N-terminal region comprises a six-stranded antiparallel 
β-barrel, a small β-sheet and an α-helix, and provides most of the residues involved in the 
FAD binding (Figure 1.9). The isoalloxazine ring of FAD is sandwiched between the 
aromatic side chain of two tyrosine residues. In 2001 the 1.7 Å resolution crystal structure 
of the recombinant corn root FNR has been shown to be very similar to the structures of 
ferredoxin−NADP+ reductases from photosynthetic tissues (spinach leaf FNR). Only a 
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sligthly different conformation of a short N-terminal extension has been found being 
maybe responsible for the different affinity for ferredoxin isoforms in photosynthetic and 
non-photosynthetic FNRs (Aliverti et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.9. Ribbon representation of plant-type FNR. In blue FAD binding domain is 
shown. In pink NADP(H) binding domain is shown and FAD prosthetic group is shown in 
yellow. 
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1.5 FERREDOXIN-NADP+ REDUCTASE OF Plasmodium falciparum 
 
 
1.5.1 PRIMARY STRUCTURE 
 
Ferredoxin-NADP+ reductase of Plasmodium falciparum (PfFNR) is encoded in the 
nucleus and then translocated in the apicoplast through a bipartite N-terminal sequence. On 
the basis of sequence alignment with other FNRs, it has been determinated that mature 
PfFNR starts at Lys56 yielding a 36 kDa protein with 316 amino acids. A comparison 
between sequences of different isoforms of FNR shows an high similarity of PfFNR with 
plant-type homologues, in particular with the homologue in non-photosynthetic tissues 
(Figure 1.10). As P. yoelii and P. knowlesi, PfFNR has not Trp residues; Trp309, 
conserved in all FNR, is substituted with a Val. Despite the most conserved residues are in 
NADPH and FAD binding sites, some significant substitutions are present in PfFNR 
sequence (Figure 1.11). In the NADPH binding domain Arg235 is substituted with a Tyr 
and Lys244 with a Ser, reducing the number of positively charged residue. Leu274, a 
residue situated in the –CGLK- binding motif of NADPH, it is substituted with an His. In 
the –LYSIAS- binding motif of FAD Ala98 is substitued with a Ser and at position 114 a 
Cys, conserved in other FNRs, is substitued with an Ala. Similarly to Apicoplexa FNRs, 
PfFNR shows two insertions of 28 and 5 amino acids respectively. The larger insertion is 
situated in proximity of FAD binding domain, the shorter is localized after the –GTG- 
motif of NADP+ binding. Moreover PfFNR posesses 6 cysteine residues, two of which are 
conserved in other FNRs (Cys132 and Cys272). 
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                              10        20        30        40        50        60        70        80        90   
                               |         |         |         |         |         |         |         |         |   
Spinach_leaf_FNR      QIASDVEAPPPAPAKVEKHSKKMEEGITVNKFKPKTPYVGRCLLNTKITGDDAPGETWH--------MVFSHEGEIPYREGQSVGVIPDGED 
Maize_root_FNR        ----SVQQASRSKVSVAPLHLESAKEPPLNTYKPKEPFTATIVSVESLVGPKAPGETCH--------IVIDHGGNVPYWEGQSYGVIPPGEN 
T.gondii_FNR          -------ATPTDQTSVDAKADELR--VAVNTFRPASPLICRVVSVTPVTSKDSSPDDSHGEAPQVFSIVLHHGKQLPFVEGQGIGIMPPSRA 
P.falciparum_FNR      ----------------------KEENNFINLYTVKNPLKCKIVDKINLVRPNSPNEVYH--------LEINHNGLFKYLEGHTCGIIPYYNE 
 
 
                              102       112       122       132       142       152       162       172       182  
                               |         |         |         |         |         |         |         |         |   
Spinach_leaf_FNR      --KNGKPHKL----------------------------RLYSIASSALGDFGDAKSVSLCVKRLIY----TNDAGETIKGVCSNFLCDLKPG 
Maize_root_FNR        PKKPGAPQNV----------------------------RLYSIASTRYGDNFDGRTGSLCVRRAVYYDPETGKEDPSKNGVCSNFLCNSKPG 
T.gondii_FNR          AQAPVADESTSQRNSVQPDGQGQQPTTVASICKRRLLPRIYSIASSRDGDDGCGSTLTLCVKKHIYADPVTGKRDRQKDGICSTYICDAKCG 
P.falciparum_FNR      LDNNPNNQINKDHNIINTTNHTNHNNIALSHIKKQRCARLYSISSSNNMEN-----LSVAIKIHKY-EQTENAPNITNYGYCSGFIKNLKIN 
 
 
                              194       204       214       224       234       244       254       264       274  
                               |         |         |         |         |         |         |         |         |   
Spinach_leaf_FNR      AEVKLTGPVGKEMLM-PK-DPNATIIMLGTGTGIAPFRSFLWKMFFE-------KHDDYKFNGLAWLFLGVPTSSSLLYKEEFEKMKEKAPD 
Maize_root_FNR        DKIQLTGPSGKIMLL-PEEDPNATHIMIATGTGVAPFRGYLRRMFME-------DVPNYRFGGLAWLFLGVANSDSLLYDEEFTSYLKQYPD 
T.gondii_FNR          DEVEVTGPVGKALLL-PT-STETPLVMLATGTGVAPFRSHLQALRRKLLSAGGPSAAQPANRPKVLLFIGARTAAAVPYMNEWRDIEAQRDG 
P.falciparum_FNR      DDIYLTGAHGYFNLPNDAIQKNTNFIFIATGTGISPYISFLKKLFAY--DKNNLYNRNSNYTGYITIYYGVYNEDSILYLNELEYFQKMYPN 
 
 
                              286       296       306       316       326       336       346       356       366 
                               |         |         |         |         |         |         |         |         | 
Spinach_leaf_FNR      NF-RLDFAVSREQTNEKGEKMYIQTRMAQYAVELWEMLKKDNTYFYMCGLKGMEKGIDDIMVSLAAAEGIDWIEYKRQLKKAEQWNVEVY 
Maize_root_FNR        NF-RYDKALSREQKNRSGGKMYVQDKIEEYSDEIFKLLD-GGAHIYFCGLKGMMPGIQDTLKKVAERRGESWDQKLAQLKKNKQWHVEVY 
T.gondii_FNR          NFVDIHFALSRQMKNPQGKKLYIQDVVWQEREKVWKALDRDGGHLYACGLKNMMVGVHEVLGNMAEEKGLPRDHLASLLKHQRRWHVEVY 
P.falciparum_FNR      NI-NIHYVFSYKQ-NSDATSFYVQDEIYKRKTEFLNLFNNYKCELYICGHKSIRYKVMDILKS---------- 
 
 
 
 
Figure 1.10: FNRs sequences alignment. Most conservative residues are shown in red, conservative substitutions are shown in green and in blue. 
Arrows indicate unconservative residues in the cofactors binding motifs. 
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  FAD BINDING DOMAIN 
 
                    95       105       115           125       135         
                     |         |         |             |         |         
Spinach_leaf_FNR   RLYSIASSALGDFGDAKSVSLCVKRLIY----TNDAGETIKGVCSNFLCDLKPG 
Maize_root_FNR     RLYSIASTRYGDNFDGRTGSLCVRRAVYYDPETGKEDPSKNGVCSNFLCNSKPG 
T.gondii_FNR       RIYSIASSRDGDDGCGSTLTLCVKKHIYADPVTGKRDRQKDGICSTYICDAKCG 
P.falciparum_FNR   RLYSISSSNNMEN-----LSVAIKIHKY-EQTENAPNITNYGYCSGFIKNLKIN 
 
 
 
 
  NADP(H) BINDING DOMAIN 
 
                           235       245       255       265       275       285 
                             |         |         |         |         |         | 
Spinach_leaf_FNR   NF-RLDFAVSREQTNEKGEKMYIQTRMAQYAVELWEMLKKDNTYFYMCGLKGMEKGIDDIM 
Maize_root_FNR     NF-RYDKALSREQKNRSGGKMYVQDKIEEYSDEIFKLLD-GGAHIYFCGLKGMMPGIQDTL 
T.gondii_FNR       NFVDIHFALSRQMKNPQGKKLYIQDVVWQEREKVWKALDRDGGHLYACGLKNMMVGVHEVL 
P.falciparum_FNR   NI-NIHYVFSYKQ-NSDATSFYVQDEIYKRKTEFLNLFNNYKCELYICGHKSIRYKVMDIL 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.2 TRIDIMENSIONAL STRUCTURE 
 
In 2007 crystallographic structure of PfFNR both in its free form and in complex with 2’-
P-AMP, an anologue of the substrate NADP(H), has been solved (Milani et al., 2007). In 
both crystal forms PfFNR crystallized as dimer stabilized by a intermolecular disulfide 
bridge between the Cys99 of each subunit (Figure 1.12). As the other plant-type FNRs, 
PfFNR consists of two domains: the N-terminal FAD binding domain, comprising residue 
1-160, and the C-terminal NADP(H) binding domain, built by residues 166-316. The FAD 
domain hosts a β-barrel built by two perpendicular three-stranded antiparallel β-sheets 
(β1β2β5 and β3 β4 β6) and a single α-helix (αA), nestled between β5 and β6. The C-
terminal domain hosts a five-stranded parallel β-sheet (β9β8β10β11), surrounded by seven 
α-helices (αB-αH).  
Figure 1.11: FAD and NADPH binding domains of FNRs. Numbering refers to spinach leaf FNR. Pink 
arrows indicate substitutions in FAD binding domain. Blue arrows indicate substitutions in NADPH 
binding domain. 
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Figure 1.12. Tridimensional structure of PfFNR (A) and PfFNR/2’-P-AMP complex (B). 
In PfFNR/2’-P-AMP complex the two monomers adopt a very close conformation 
involving 2’-P-AMP binding site. Conversely, in the PfFNR free form contact area 
between the two monomers is around Cys99. 
Cys99 
A 
B 
Cys99 
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In both crystal forms PfFNR displays five disordered surface regions: the N-terminal 
residues 1-4, the long loop between β3 and β4 (residues 63-97), the β5- αA loop (residues 
126-133), the αB-β9 loop (residues 196-205), and the αH- αI loop (residues 299-305). 
The FAD molecule is observed essentially in the same extended conformation in both 
crystal forms. The isoalloxazine ring is hosted in a pocket between the two protein 
domains, sandwiched between the conserved C-terminal Tyr316 and four conserved amino 
acids residues of the β4 strand. The overall FAD binding mode described for PfFNR is 
essentially conserved in other plant-type FNRs, the main conformational differences 
affecting only the protein surface location of the cofactor’s adenosine moiety. However 
given the location of the adenine ring far from the active site region, such structural 
variation should bear little relevance for PfFNR catalysis.  
The most significative differences between PfFNR and other FNRs structure are located in 
the 2’-P-AMP binding site (Aliverti et al., 2008). (i) The ligand interacts by hydrogen bond 
with two regions of the C-terminal domain (Ser247, Tyr258, Gln260, His286 and Ser288) 
and with Lys119 of the N-terminal domain. (ii) The negative charge of the 5’-phosphate is 
balanced by Lys119 and by His286, whereas there are no positevely charged residues 
balancing the negative charge of the 2’-phosphate. A compensation can be offer by Lys287 
and/or Lys292 from the opposing subunit in the dimeric assembly, suggesting that the 
achievement of inter-molecular electrostatic balance at the 2’-phosphate might be one of 
the driving forces guiding PfFNR dimerization induced by 2’-P-AMP or by NADP+. In 
SoFNR the 2’-phosphate charge is compensated intramolecularly by the highly conserved 
residues Arg235 (Tyr248 in PfFNR) and Lys244 (Ser256 in PfFNR). (iii) The 2’-P-AMP 
adenine moiety is sandwiched between Tyr258 and His286. 
The mosts stricking differences between PfFNR structure in free form and in complex with 
2’-P-AMP are located in the NADP(H) binding domain. As can be seen in Figure 1.13, 
both the β9-αF loop (residues 248-257) and the αH helix (residues 289-298) undergo 
notably structural transistions: in absence of 2’-P-AMP, the loop is shortened by seven 
residues while the helx is elongated by two turns and is shifted towards the FAD binding 
pocket by about 2 Ǻ. 
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Figure 1.13. Structure of PfFNR (yellow ribbon) is overlaid on the structure of 
PfFNR/2’-PAMP complex (blue ribbon). The lower right part highlights the 
conformational helix-coil transition occurring at the β9-αF loop, in the NADP(H) binding 
domain in absence of 2’-P-AMP. 
 
 
1.5.3 FUNCTIONAL PROPERTIES 
 
In 2005 it has been demonstrated that the ferredoxin/ferredoxin-NADP+ reductase redox 
system of P. falciparum serves as the physiological electron donor for LytB, the enzyme 
which catalyses the last step of the DOXP pathway of isoprenoids biosynthesis in 
apicoplast (Rohrich et al., 2005). This results represents the first evidence of a direct 
involvement of PfFNR in apicoplast metabolism. An interesting feature of PfFNR, unique 
among plasmodial reductase, is its ability to undergo dimerization and this process is 
favoured by the presence of either 2’-P-AMP or NADP+. Dimer relies on the oxidation of 
residue Cys99 in two opposing subunits and it has been found to be essentially inactive, 
but full activity is recovered upon disulfide reduction (Milani et al., 2007, Balconi et al., 
2009). Similar regulatory mechanism has been observed in plant non-photosynthetic 
plastid where thioredoxins are held to play a central role in redox regulation (Balmer et al., 
2006). It has been suggested that two thioredoxins (Trx2 and Trx3) are apicoplast-resident, 
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based on the detection of a predicted signal peptide at the N-terminus (Nickel et al., 2006). 
Apicoplast-resident thioredoxin would require a thioredoxin reductase (TrxR), but the 
TrxR in P. falciparum is cytosolic. Therefore, alternative redox regulators should be 
sought to prevent dimerization in vivo. 
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AIM OF THE PROJECT 
 
 
 
 Malaria is recognised as one of the major health priorities by the World Health 
Organization. The most severe form of the disease, tropical malaria, is caused by 
Plasmodium falciparum. The diffusion of pathogenic strains, resistant to traditional 
antimalarial treatments, urgently requests the development of new therapies. P. falciparum 
belongs to Apicomplexa, a phylum consisting of unicellular, obligate intracellular parasites 
which possess an organ of algal origin, the apicoplast. This organelle has been shown to be 
required for pathogen survival becoming a known site of action of antimalarial 
compounds. In the apicoplast of P. falciparum a ferredoxin-NADP+ reductase (PfFNR) has 
been identified. This enzyme, in conjunction with ferredoxin, is directly involved in the 
electron transfer from NADPH to LytB which catalyzes the last step of the mevalonate-
independent isoprenoid biosynthesis, an essential pathway of the parasite. The 
crystallographic structure of PfFNR revealed that the enzyme binds the substrate 
NADP(H) in an unusual way respect to other FNRs and showed that in the NADP(H) 
binding site are located two basic residues, His286 and Lys249 conserved within the 
Plasmodium genus but not in other plant-type homologues.  
 Aim of this work has been to clarify the role of His286 and Lys249 in substrate 
binding and catalysis, and to identify and characterize a first set of PfFNR inhibitors, 
selected by different approaches. In particular, I have undertaken the characterization of 
variants of PfFNR obtained by site-directed mutagenesis, in which His286 and Lys249 
have been replaced. Moreover I studied in vitro a series of enzyme inhibitors selected by 
virtual screening, exploiting the enzyme tridimensional structure, and by screening of a 
compounds library.  
 The features of PfFNR, highligthed by the studies that I performed on the various 
enzyme forms, make PfFNR an attractive drug target, suitable for the development of 
novel antimalarial compounds. 
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2 
 
MATERIALS AND METHODS 
 
2.1 MOLECULAR BIOLOGY 
 
2.1.1 SITE-DIRECTED MUTAGENESIS AND PLASMID CONSTRUCTION 
 
Amino acyl replacements were introduced in the gene encoding wt PfFNR and PfFNR-
C99A, using the QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene). The 
procedure was carried out following the manifacturer’s instructions, using the plasmid 
pET-PfFNR as the template for the replacements of His286 and Lys249, and pET-PfFNR-
C99A for the replacement of Cys284. The couples of complementary oligonucleotides 
used are shown in Table 2.1. The plasmids carrying the mutations were named pET-
PfFNR-K249A, pETPfFNR-C99A-C284S, pET-PfFNRH286L, pET-PfFNR-H286K, pET-
PfFNR-H286Q and pET-PfFNR-H286A, respectively. All these plasmids direct the 
expression of the respective PfFNR forms with an N-terminal His-tag. The insert of all 
expression plasmids was fully sequenced to exclude the presence of artifacts.  
Table 2.1. Oligonucleotide primers used for the mutagenesis  
Underlined nucleotides indicate mismatches sites in the mutagenesis primers.  
Primer Nucleotide sequence 
Lys249Ala 5’-TATACATTATGTTTTCTCTTATGCACAAAATTCAGATGCAACAAG-3’ 
Lys249Ala 5’-CTTGTTGCATCTGAATTTTGTGCATAAGAGAAAACATAATGTATA-3’ 
Cys284Ser 5’-TAATTATAAATGTGAATTATATATAAGTGGTCACAAATCAATAAG-3’ 
Cys284Ser 5’-CTTATTGATTTGTGACCACTTATATATAATTCACATTTATAATTA-3’ 
His286Leu 5’-GAATTATATATATGTGGTCTGAAATCAATAAGATATAAAGTTATG-3’ 
His286Leu 5’-CATAACTTTATATCTTATTGATTTCAGACCACATATATATAATTC-3’ 
His286Lys 5’-GAATTATATATATGTGGTAAAAAATCAATAAGATATAAAGTTATG-3’ 
His286Lys 5’-CATAACTTTATATCTTATTGATTTTTTACCACATATATATAATTC-3’ 
His286Gln 5’-GAATTATATATATGTGGTCAGAAATCAATAAGATATAAAGTTATG3’ 
His286Gln 5’-CATAACTTTATATCTTATTGATTTCTGACCACATATATATAATTC-3’ 
His286Ala 5’-GAATTATATATATGTGGTGCCAAATCAATAAGATATAAAGTTATG-3’ 
His286Ala 5’-CATAACTTTATATCTTATTGATTTGGCACCACATATATATAATTC-3’ 
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The ORF encoding the mature form of PfFNR-C99A was excised from pET-PfFNR as a 
NcoI/XhoI fragment and inserted in a customized version of vector pET SUMO 
(Invitrogen) containing unique NcoI and XhoI restriction sites yielding the plasmid pET-
SUMO-PfFNR-C99A (Figure 2.1). The resulting recombinant protein polyHis-SUMO-
PfFNR-C99A is a fusion composed by a polyHis-tag, a small ubiquitin-like modifier 
(SUMO) unit and PfFNR-C99A. After the cleavage with the SUMO-specific Senp2 
protease, polyHis-SUMO-PfFNR-C99A is expected to yield a PfFNR-C99A form that 
includes extra Ser, Met and Gly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Map of pET-SUMO-PfFNR-C99A. 
 34 
2.2 PROTEIN OVEREXPRESSION AND PURIFICATION 
 
2.2.1 EXPRESSION TEST OF Poly-His-SUMO-PfFNR-C99A 
 
E. coli cells Rosetta (DE3) transformed with the plasmid pETSUMO-PfFNR-C99A were 
used to inoculate 2xYT medium (500 ml) containing 30 µg/ml kanamycine and grown at 
20 °C under orbital shaking (220 rpm). When the A600 of the colture reached a value of 
about 0.8, induction was obtained by addition of isopropyl-thio-β-galactoside (IPTG, 0.1 
mM, final concentration). Aliquots of cells were harvested at different times after IPTG 
addition by centrifugation. To prepare soluble extracts, each aliquot of cells was 
resuspended in 50 mM NaH2PO4,  pH 8.0, containing 500 mM NaCl, 5 mM imidazole,  1 
mM β-mercaptoethanol and Complete EDTA-free protease inhibitor cocktail (Roche) 
according to manifacturer’s instructions. The cell suspensions were disrupted by sonication 
with Branson Model 250 Sonifier (6 x 10 s cycles). Each crude extract was obtained by 
centrifugation at 13000 rpm for 45 min at 4 °C. Aliquots of each crude extract were used 
for protein and activity assays and SDS-PAGE. 
 
2.2.2 PURIFICATION OF PfFNR-C99A AS CLEAVABLE FUSION WITH SUMO PROTEIN 
 
E. coli cells Rosetta (DE3) harboring the plasmid pETSUMO-PfFNR-C99A were used to 
inoculate 200 ml of 2xYT medium containing kanamycine at final concentration 30 µg/ml. 
The colture was grown overnight under orbital shaking (220 rpm) at 37 °C and was used to 
inoculate 12 l of 2xYT medium at 20 °C containing 30 µg/ml kanamycine in a bioreactor. 
When the colture reached an optical density at 600 nm between 0.8 and 1, IPTG was added 
to a final concentration of 0.1 mM. Expression of poly-His-SUMO-PfFNR-C99A was 
induced for 24 hours. Cells were harvested by centrifugation at 6000 rpm in a Sorvall GSA 
rotor for 10 min at 4 °C. Tipically, 6 g of wet cell paste was obtained from 1 liter of cells 
colture. The cell paste was suspended in 2.5 volumes of 50 mM NaH2PO4, pH 8.0 
containing 500 mM NaCl, 5 mM imidazole, 1 mM β-mercaptoethanol and Complete 
EDTA-free protease inhibitor cocktail (Roche) according to manifacturer’s instruction. 
Then the cell suspension was disrupted by sonication with Branson Model 250 Sonifier (6 
x 1 min cycles). The crude extract was obtained by centrifugation for 60 min at 18000 rpm 
and 4 °C in a Sorvall SS34 rotor. After centrifugation aliquots of crude extract were used 
for NADPH-K3Fe(CN)6 reductase activity, protein assay and SDS-PAGE. The soluble 
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fraction was loaded on HisTrapTM HP column prepacked with precharged Ni SepharoseTM 
High Performance (GE Healthcare) and equilibrated in 50 mM NaH2PO4, pH 8.0 
containing 500 mM NaCl, 5 mM imidazole, 10% glycerol and 1 mM β-mercaptoethanol 
(Buffer A). The molarity of imidazole in the buffer A was brought to 20 mM and then used 
for extensive washing. Poly-His-PfFNR-C99A was eluted with 200 mM imidazole in 
buffer A. After the column, the enzyme has been desalted by gel filtration on Hi TrapTM 
Desalting column (Amersham Biosciences) equilibrated in 50 mM Tris-HCl, pH 7.4 
containing 200 mM NaCl, 10% glycerol and 1 mM DTT.  
The hexahistidine affinity tag and SUMO moiety were removed by digestion with Poly-
His-senp2 protease using a ratio 1/70 (w/w) between protease and Poly-His-PfFNR-C99A. 
The digestion mixture was incubated at 20 °C for 30 min. In order to separate the cleaved 
protein from both protease and the residual uncleaved protein, the digestion mixture was 
loaded on Ni SepharoseTM High Performance column exploiting the affinity, altough weak, 
of mature PfFNR-C99A for the resin. For this second purification step the same buffer was 
used as the previous step on Ni SepharoseTM High Performance (GE Healthcare) column. 
PfFNR-C99A was eluted with 20 mM imidazole. Then the mature PfFNR-C99A was 
desalted by gel filtration on Hi TrapTM Desalting column (Amersham Biosciences) 
equilibrated in 50 mM Tris-HCl, pH 7.4 containing 10% glycerol and 1 mM DTT.  
 
 
2.2.3 PURIFICATION OF PfFNR FORMS 
 
For the overproduction of PfFNR-H286K, PfFNR-H286L, PfFNR-H286Q, PfFNR-
H286A, PfFNR-K249A and PfFNR-C99A-C284S, E. coli Rosetta (DE3) cells harboring 
the plasmids pET-PfFNR-H286L, pET-PfFNR-H286K, pET-PfFNR-H286Q and pET-
PfFNR-H286A, pET-PfFNR-K249A, pETPfFNR-C99A-C284S, respectively, were used to 
inoculate 200 ml of 2xYT medium containing kanamycine at final concentration 30 µg/ml. 
The colture was grown overnight under orbital shaking (220 rpm) at 37 °C and was used to 
inoculate 5 x 0.5 l of the same liquid colture medium at 20 C°, 220 rpm. When the colture 
reached an optical density at 600 nm between 0.8 and 1, IPTG was added to a final 
concentration of 0.1 mM. Expression of the PfFNR forms was induced for 24 hours. Cells 
were harvested by centrifugation at 6000 rpm in a Sorvall GSA rotor for 10 min at 4 °C. 
Tipically, 15 g of wet cell paste was obtained from 2.5 l of cells colture. The cell paste was 
suspended in 2.5 volumes of 50 mM NaH2PO4, pH 8.0, 500 mM NaCl, 5 mM imidazole, 1 
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mM PMSF and 1 mM β-mercaptoethanol, and was disrupted by sonication with Branson 
Model 250 Sonifier (6 x 1 min cycles). The crude extract was obtained by centrifugation 
for 60 min at 18000 rpm and 4 °C in a Sorvall SS34 rotor. After centrifugation aliquots of 
crude extract were used for NADPH-K3Fe(CN)6 reductase activity, protein assay and SDS-
PAGE. The clarified cell-free extract was loaded on a Ni SepharoseTM High Performance 
column (GE Healthcare) pre-equilibrated in 50 mM NaH2PO4,  pH 8.0 containing 500 mM 
NaCl, 5 mM imidazole, 10% glycerol and 1 mM β-mercaptoethanol (Buffer A). Extensive 
washing was performed with buffer A containing 20 mM imidazole. The enzyme was 
eluted with a 20-500 mM imidazole gradient under the conditions recommended by the 
resin manufacturer. The best fractions were pooled together, 5 mM EDTA was added, and 
ammonium sulfate was added to 15% saturation, for chromatography on a Phenyl-
Sepharose High Performance column (GE Healthcare). Ammonium sulfate in a decreasing 
gradient of saturation from 15% to 0% in buffer B (50 mM Tris-HCl, pH 7.4, containing 
10% glycerol and 1 mM DTT) was used to elute the enzyme. The best fractions were 
pooled and precipitated at 70% ammonium sulfate saturation. The enzyme was solubilized 
in buffer B and desalted on a Hi TrapTM Desalting column (Amersham Biosciences). After 
incubation for 48 hours at 16 °C with 1/500 (w/w) Factor Xa (Pierce) to cleave off the His-
tag, the mixture was loaded again on a Ni SepharoseTM High Performance column (GE 
Healthcare). Owing to the moderate intrinsic affinity of PfFNR forms to the nickel ion, the 
enzyme was retained by the column even in the absence if the His-tag, and was specifically 
eluted with 20 mM imidazole. The FNR-containing fractions were concentrated by 
ultrafiltration, desalted by gel filtration on a Hi TrapTM Desalting column (Amersham 
Biosciences), and stored at -80 °C in 50 mM Tris-HCl , pH 7.4 containing 10% glycerol 
and 1 mM DTT. 
 
2.3 PROTEIN ASSAYS 
 
Protein concentration of crude extract was determined with the Biuret method (Thieler H. 
et al., 1966) and that of all the other sample by the Bradford method ( Bradford M., 1976), 
with bovine serum albumine (BSA) as the reference protein, using Amresco Bradford 
Reagent. 
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2.4 SDS-PAGE 
 
SDS-PAGE was carried out on 8x10 cm, 1.5 mm thick gels in a Hoefer SE260 apparatus 
using the Laemmli method (Laemmli U. K., 1960). Total acrylamide/bis-acrylamide 
concentration in running gels was 12%. Gels were stained with Comassie Blue and 
destained by diffusion in 30% ethanol and 10% acetic acid. 
 
 
2.5 WESTERN BLOT 
 
For Western analysis, soluble extract and proteins fractionated by SDS-PAGE were 
transferred to Hybond-C extra membrane (Amersham Pharmacia Biotech) using blotting 
apparatus (BioRad). The blot was incubated with the anti-PfFNR polyclonal serum, and 
immunodetection was performed using Anti-rabbit IgG alkaline phosphatase conjugated. 
 
 
2.6 N-TERMINAL SEQUENCE ANALYSIS 
 
For N-terminal sequence analysis determination both the mature and the truncated PfFNR-
C99A were electroblotted on a PVDF membrane and analyzed by a pulsed-liquid 
sequencer equipped with a PHT analyser (Procise model 491, Applied Biosystems) in the 
Prof. Gabriella Tedeschi laboratory (Dipartimento di Patologia Animale, Igiene e Sanità 
Pubblica Veterinaria, Università degli Studi di Milano, Milan, Italy). 
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2.7 ACTIVITY ASSAYS 
 
2.7.1 STEADY-STATE KINETICS 
 
2.7.1.1  STANDARD ACTIVITY 
 
Standard diaphorase activity was measured in 1 ml of reaction mixture containing: 
 
  2 µg/ml  Glucose-6-phosphate dehydrogenase 
  0.1 mM   NADP+ 
  2.5 mM   Glucose-6-phosphate 
  100 mM  Tris-HCl pH 8.2 
  1 mM    K3Fe(CN)6 
After the addition of ~ 25 nM PfFNR forms, reaction was monitored 
spectrophotometrically by following ferricyanide reduction at 420 nm (ε420 = 1.025        
mM-1cm-1). The standard activity is expressed in U/mg (µmol of product/min/mg of 
enzyme) or in U/FAD (µmol of product/min/µmol of enzyme) and it has been measured 
after each chromatographic step. 
 
Standard activity using DCPIP as artificial electron acceptor was determined in 1 ml 
reaction mixture containing: 
 
  2 µg/ml  Glucose-6-phosphate dehydrogenase 
  0.1 mM   NADP+ 
  2.5 mM   Glucose-6-phosphate 
  100 mM  Tris-HCl pH 8.2 
  30 µM   DCPIP 
 
After the addition of ~ 7.5 nM PfFNR, reaction was monitored spectrophotometrically by 
following DCPIP reduction at 600 nm (ε600 = 21.4 mM-1cm-1). 
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Standard activity using cytochrome c as electron acceptor was determined in 1 ml reaction 
mixture containing: 
 
  0.1 mM   NADPH 
  43 µM   cytochrome c 
  100 mM  Tris-HCl pH 8.2 
 
After the addition of ~ 15 nM PfFNR forms, reaction was monitored 
spectrophotometrically by following cytochrome c reduction at 550 nm (ε550= 19.5 mM-
1cm-1). The following reaction mechanism has been considered: 
 
  
 
 
         where I = I24 or I27 
 
 
Standard activity using p-iodonitritetrazolium (INT) as electron acceptor was determined 
in 1 ml reaction mixture containing: 
 
  0.1 mM   NADPH 
  50 mM   NaCl 
  100 mM  MOPS-NaOH pH 7 or 100 mM Tris-HCl pH 8.2 
  0.1 mM  INT 
  60 µM   compound of Prestwick Chemical Library 
 
After the addition of ~ 10 nM PfFNR, reaction was monitored by following the appearance 
of a pink coloration indicating the progress of the reaction. 
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2.7.1.2  DETERMINATION OF KINETIC PARAMETERS 
 
Steady-state kinetic parameters for NAD(P)H-K3Fe(CN)6 reductase reaction and NADPH-
DCPIP reductase reaction were determined by varying independently the concentration of 
both NAD(P)H and the electron acceptor. The NADH- K3Fe(CN)6  reductase activity of 
the PfFNR-K249A form was measured omitting the NADPH-regenerating system. Initial 
velocity data were fitted to the equation for a competitive inhibition (1) in the case of 
ferricyanide and for a ping-pong bi-bi (2) in the case of DCPIP. The inhibitory effect of  
2’-P-AMP on the NADPH-DCPIP reductase reaction catalyzed by the PfFNR forms was 
studied by independently varying the concentration of NADPH and that of the inhibitor at 
a fixed concentration of DCPIP (20 µM). Initial velocity data were then fitted to the 
equation for a competitive inhibition (1). 
 
 
            (1) 
 
 
 
        Ki = competitive inhibition constant 
        I = inhibitor 
 
 
 
            (2) 
 
 
        A = NADPH 
        B = electron acceptor (DCPIP) 
        KA, KB = Michaelis constants 
 
 
Steady-state kinetic parameters for NADPH-K3Fe(CN)6 reductase reaction at different pH 
were determined as described above. From pH 6.25 to 8 the activity was assayed in 50 mM 
sodium phosphate and from pH 8.5 to 10.25 it was assayed in 50 mM sodium carbonate.  
 41 
2.7.1.3  DETERMINATION OF IC50 OF INHIBITORS 
 
Both NADPH-K3Fe(CN)6 reductase reaction and NADPH-DCPIP reductase reaction were 
used to determine IC50 values omitting the NADPH-regenerating system. The reaction 
mixture contained: 
 
  100 mM   Tris-HCl pH 8.2 
  0.1 mM  NADPH 
 
Moreover it has been added to the mixture increasing concentrations of inhibitor and 1 mM 
K3Fe(CN)6, in the case of NADPH-K3Fe(CN)6 reductase reaction, and 30 µM DCPIP, in 
the case of NADPH-DCPIP reductase reaction. The initial velocity data were reported as 
percentage of residual activity  and were fitted to the equation for determination of 
parameter IC50 (3): 
 
 
 
           (3) 
 
 
         x = % residual activity 
         s = slope factor 
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2.7.1.4  DETERMINATION OF INHIBITION CONSTANT OF COMPOUNDS 
SELECTED BY VIRTUAL SCREENING 
 
Inhibition constants values (Ki) were determined for the NADPH-K3Fe(CN)6 reductase 
reaction and NADPH-DCPIP reductase reaction as described in paragraph 3.7.1.2. The 
electron acceptor concentration has been kept constant, 30 µM DCPIP and 100 µM 
K3Fe(CN)6 respectively. In order to evoid that ferricyanide inhibitor effect interferes with 
that of the compounds analyzed, K3Fe(CN)6 concentration was lower in comparison with 
standard acitivity assays. Initial velocity data were then fitted to the equation for a mixed 
inhibition (4) describing an inhibitory effect which affects both the apparent kcat/Km and kcat 
of the enzyme. This analysis provides two inhibition constants Ki and Ki’. 
 
 
 
 
            (4) 
 
 
 
       Ki = competitive inhibition constant 
       Ki’ = uncompetitive inhibition constant 
       I = inhibitor 
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2.8 INHIBITION STUDIES WITH EBSELEN 
 
2.8.1 SPECTROPHOTOMETRIC ANALYSIS 
 
2.8.1.1 KINETIC OF EBSELN INHIBITION OF PfFNR 
 
Standard diaphorase activity with ferricyanide was measured for PfFNR-C99A, PfFNR-
C99A-C284S, SoFNR, SoFNR-C272S and FprA as described in paragraph 3.7.1.1 in 
presence of different concentrations of ebselen. The same reactions were carried out in 50 
mM HEPES-NaOH pH 7.0. Each time course was fitted with curves describing the slow 
onset of complete enzyme inactivation during the assay, according to a single exponential 
decay (5). 
 
 
            (5) 
 
 
     A = absorbance at time t 
     A0 = initial absorbance 
     vi = initial velocity of the catalyzed reaction 
     vs = steady-state (final) velocity of the catalyzed reaction 
     k = apparent kinetic constant of EI formation 
     t = reaction time 
 
 
 
Apparent kinetic constant (k) values in function of ebselen concentrations were consistent 
with a simple bimolecular mechanism. The second order inhibition rate constant (kebselen) 
were calculated by using equation (6): 
 
    k = kebselen [ebselen]    (6) 
 
 
k
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2.8.1.2 CHARACTERIZATION OF EBSELEN IRREVERSIBLE INHIBITION 
 
PfFNR-C99A (2 µM) and wt PfFNR (2 µM) were incubated in 50 mM TrisHCl pH 7.4, 
10% glycerol with 10 µM ebselen at 25 °C. Aliquots of the incubation mixture were 
withdrawn periodically and diluted in the standard NADPH-K3Fe(CN)6 reductase assay 
mixture (see paragraph 3.7.1.1).  
 
 
2.8.1.3 EFFECT OF REDUCED GLUTATHIONE ON EBSELEN INHIBITION 
 
PfFNR-C99A (2 µM) was incubated in 50 mM TrisHCl pH 7.4, 10% glycerol with 0.1 mM 
GSH at 25 °C either with or without ebselen. Aliquots of the incubation mixture were 
withdrawn periodically and diluted in the standard NADPH-K3Fe(CN)6 reductase assay 
mixture (see paragraph 3.7.1.1).  
 
 
2.8.1.4 EFFECT OF NADPH ON EBSELEN INHIBITION 
 
Standard diaphorase activity with ferricyanide was measured for PfFNR-C99A as 
described in paragraph 3.7.1.1 in presence of different concentrations of NADPH, keeping 
constant ebselen concentration (10 µM). Each time course was fitted with equation (5).  
 
 
2.8.1.5 EFFECT OF EBSELEN TARGETING THE Cys RESIDUES 
 
wt PfFNR (2 µM), PfFNR-C99A (2 µM) and PfFNR-C99A-C284S (25 µM) were 
incubated in 50 mM HEPES-NaOH, pH 7.0 with different concentrations of ebselen 
yielding an inhibitor/enzyme molar ratio between 0.5/1 and 10/1. Aliquots of the 
incubation mixture were withdrawn periodically and diluted in the standard NADPH-
K3Fe(CN)6 reductase assay mixture (see paragraph 3.7.1.1) untill no variation of residual 
activity was observed.  
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2.8.2 SPECTROFLUORIMETRIC ANALYSIS 
 
Studies about FAD release from PfFNR forms promoted by ebselen were performed 
spectrofluorimetrically at 25 °C using spectrofluorimeter Cary Eclipse (Varian). PfFNR-
C99A (1 µM) and PfFNR-C99A-C284S (1 µM) were incubated either in 100 mM HEPES-
NaOH, pH 7.0 or 100 mM TrisHCl, pH 8.2 in presence of different ebselen concentrations. 
Flavin fluorescence was measured as emission wavelength at 530 nm after an excitation at 
450 nm. 
 
 
2.9 NADP+ TITRATION OF PfFNR FORMS  
 
Titration of oxidized PfFNR forms with NADP+ were performed spectrophotometrically at 
15 °C. The enzyme was diluted to a final concentration of about 20 µM in 50 mM         
Tris-HCl, pH 7.6 using a Cary 100 (Varian) double-beam spectrophotometer. Difference 
spectra were computed by subtracting from each spectrum that obtained in absence of 
ligand, after correction for dilution. Kd values were obtained by fitting data sets by non-
linear regression to the theoretical equation (7) for a 1:1 binding, using the GraFit 4.0 
software (Erythacus Software Ltd, Staines, UK). ∆A is the value of the difference spectrum 
at a selected wavelength; ∆ε is the difference extinction coefficient at that wavelength of 
the protein-ligand complex. 
 
 
            (7) 
 
 
 
 
 
[L]a = concentration of ligand stock solution 
  Va = volume of ligand added 
[P]i = protein initial concentration 
   Vi = initial volume of reaction mixture 
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2.10    PHOTOREDUCTION EXPERIMENTS 
 
Anaerobic stepwise photoreduction of the FAD prosthetic group of PfFNR forms was 
performed by the light/EDTA system. In particular the PfFNR forms reduction was 
achieved by one-electron donation from 5-carba-5-deazariboflavin semiquinone produced 
by light irradiation, to EDTA serving as the final electron source. Photoreductions were 
performed in presence of NADP+ and the reactions were carried out at 15 °C in an 
anaerobic cuvette on ~15 µM PfFNR samples in 50 mM HEPES-NaOH, pH 7.0 containing 
10% glycerol, 13 mM EDTA and 1.3 µM 5-carba-5-deazariboflavin. NADP+ was at a 1.2 
molar ratio with respect to the enzyme. Reaction solutions were made anaerobic by 
successive evacuation and flushing with O2-free N2. Each mutant was subject to successive 
short times of illumination to finally reach full reduction of enzyme flavin. Absorption 
spectra were recorded before and after successive periods of irradiation.  
 
 
2.11 RAPID KINETICS 
 
Wild-type or mutant PfFNRs (17-20 µM) were reacted with NADPH (0.025-2 mM) at      
25 °C in 50 mM HEPES-NaOH, pH 7.0 under anaerobic conditions, using an SF-61 DX2 
diode-array stopped-flow spectrophotometer (Hi-Tech Scientific, Bradford-upon-Avon, 
UK). Briefly, anaerobiosis in the instrument syringes and plumbing was achieved by 
flushing them with anaerobic 5 mM sodium dithionite in 50 mM Tris-HCl, pH 8.5, which 
was allowed to scavenge oxygen overnight. Two hours prior to the beginning of the 
experiment, the dithionite solution was substituted with anaerobic buffer. Prior to stopped-
flow studies, enzymes were gel filtered in PD-10 column in 50 mM HEPES-NaOH, pH 7.0 
and were made anaerobic in a tonometer by repeated cycles of evacuation and flushing 
with O2-free N2. Substrate solutions were instead made anaerobic by bubbling nitrogen 
through them for at least 15 min. The rate of flavin reduction was measured by monitoring 
the decrease in absorbance at 454 nm that results from the decreasing of oxidized flavin 
upon mixing the enzyme with the substrate. A set of 300 spectra within the 300-700 nm 
wavelength range was recorded from each shot over total reaction times ranging from 0.5 
to 7 s. Absorbance traces at different wavelengths were fitted to exponential decay 
equations using KinetAsyst version 3.0 (Hi-Tech Scientific).  
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2.12 CRYSTALLIZATION OF PfFNR-H286K AND PfFNR-H286L 
 
In collaboration with Dr. Mario Milani, Università degli Studi di Milano, recombinant 
PfFNR-H286K and PfFNR-H286L were crystallized in batch setup under a 1:1 mixture of 
paraffin and silicon oils, using an Oryx 8 robot (Douglas instruments). PfFNR-H286K was 
25 mg/ml in 50 mM Tris-HCl, pH 7.4, containing 1 mM DTT, 2 mM 2’-P-AMP. The well 
solutions consisted of 20% 2-propanol, 20% PEG 4000 and 0.1 M citrate-NaOH, pH 5.4. 
Crystal grew under these conditions in ~ 2 weeks.  
PfFNR-H286L was crystallized both in its free form and in complex with 2’-P-AMP. 
Crystals of PfFNR-H286L were obtained by mixing 35 mg/ml PfFNR-H286L in 50 mM 
Tris-HCl, pH 7.4, containing 1 mM DTT with 1.6 M citrate-NaOH, pH 6.5, while crystals 
of the PfFNR-H286L-2’-P-AMP complex were obtained by soaking a crystal (grown in 
12% PEG 6000, 5% glycerol, 0.1 M cacodylate-NaOH pH 6.5) in a stabilizing solution 
(18% PEG 6000, 5% glycerol, 0.1 M cacodylate-NaOH pH 6.5 and 3 mM 2’-P-AMP) 
containing the ligand. Both the crystal forms grew in ~ 3 weeks.  
All the crystals were soaked in a cryoprotectant solution obtained by adding up to 25% 
glycerol to the respective precipitating solution and flash-cooled in liquid nitrogen. X-ray 
diffraction data were collected at the ID23-1 beamline of ESRF (Grenoble) and at Elettra, 
Trieste, XRD1.  
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3 
 
RESULTS 
 
 
3.1 INHIBITION STUDIES AND CHARACTERIZATION OF COMPOUNDS 
ACTIVE AGAINST PfFNR 
 
3.1.1      STRUCTURE-BASED VIRTUAL SCREENING 
 
In collaboration with Dr. Mario Milani and Prof. Martino Bolognesi (Università degli Studi 
di Milano), an in silico screening of two virtual libraries of compounds was performed, in 
order to identify novel molecules inhibiting PfFNR. The program AutoDock (Goodsell, 
D.S. et al., 1996) was used to study the interaction of small, flexible ligands to the known 
structure of PfFNR. AutoDock was run on two virtual libraries, LOPAC and Diversity Set. 
The ~1900 compounds of Diversity Set have been isolated by the Developmental 
Therapeutics Program of the National Cancer Institute whereas LOPAC is obtained from 
Sigma-Aldrich and it contains ~1300 drug-like compounds, pharmacologically active and 
commercially available with an high grade purity.  
Since the crystal structure of PfFNR was obtained in complex with 2’-P-AMP, the binding 
site of the substrate analogue was chosen as the target for the screening. Autodock 
calculates the interaction energy considering deformation energy of the ligand, loss of 
conformational entropy and desolvatation energy.  
With this approach, 34 compounds were identified with binding energy for PfFNR similar 
or better than that of 2’-P-AMP.  
I have experimentally characterized 16 out of these 34 compounds in order to evaluate 
their actual action on the catalytic properties of PfFNR. 
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3.1.1.1      DETERMINATION OF IC50 
 
The IC50 is the concentration of inhibitor that provides 50% inhibition of the target 
enzyme. I evaluated this parameter measuring PfFNR catalytic activity using two different 
artificial substrate as electron acceptors: potassium ferricyanide (K3Fe(CN)6) and 
dichlorophenolindophenol (DCPIP) a one-electron and two-electron acceptor, respectively. 
 
3.1.1.1.1      INHIBITION OF NADPH- K3Fe(CN)6 REDUCTASE REACTION 
 
I found that four compounds, I19, I21, I23 and I27, were able to efficiently inhibit PfFNR 
with an IC50 equal or less than 10 µM, as shown in Table 3.1.  
In some cases it was not possible to obtain an IC50 value: compound I29 displayed an IC50 
value too high to be determined,  while compound I23, because of its high absorbance at 
420 nm, made difficult to monitor the reduction of  K3Fe(CN)6 preventing a reliable 
measure of residual enzymatic activity. Finally, compound I32 was found to interfere with 
the enzyme assay, because it turned out to be a good catalyst itself of the reduction of 
K3Fe(CN)6 by NADPH. 
 
3.1.1.1.2 INHIBITION OF NADPH- DCPIP REDUCTASE REACTION 
Inhibitor IC50 K3Fe(CN)6 (µM) 
 
Inhibitor IC50 K3Fe(CN)6  (µM) 
I8 47.1 ± 2.6  I27 9.6 ± 0.5 
I19 10.8 ± 0.9  I28 115 ± 6 
I21 0.170 ± 0.007  I29 / a 
I22 299 ± 14  I30 2116 ± 817 
I23 / b   I31 221 ± 41 
I24 2.05 ± 0.04  I32 / b 
I25 53.2 ± 3.1  I33 226 ± 38 
I26 84.9 ± 1.3  I34 193 ± 6 
  
 a
: not determined because of the high inhibition constrant of the compound 
 b
: not determined because the compound interfere with the measurement of reaction rate  
 
Table 3.1. IC50 for NADPH-K3Fe(CN)6 reductase reaction catalized by PfFNR. 
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3.1.1.1.2      INHIBITION OF NADPH- DCPIP  REDUCTASE REACTION 
In order to confirm the results described in the previous paragraph, I measured the IC50 for 
the NADPH-DCPIP reductase reaction.  As shown in the Table 3.2, the activity with 
DCPIP is more sensitive to inhibition than the activity with K3Fe(CN)6. In particular  I19, 
I21, I24 and I27 have an IC50  lower than 2 µM, while I29 was confirmed to be a very poor 
inhibitor of PfFNR. The study of NADPH-DCPIP reductase reaction allowed to determine 
the IC50 for I23 and I32, even if these value were rather high. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inhibitor 
IC50DCPIP   
(µM)  Inhibitor 
IC50DCPIP   
(µM) 
I8 10.3 ± 0.2  I27 0.78 ± 0.03 
I19 1.8 ± 0.7  I28 25.6 ± 0.5 
I21 0.076 ± 0.003  I29 - 
I22 160 ± 6  I30 257 ± 11 
I23 36 ± 1  I31 97.8 ± 5.3 
I24 0.75 ± 0.02  I32 755 ± 51 
I25 20.7 ± 0.7  I33 76.7 ± 2.9 
I26 25.6 ± 0.5  I34 380 ± 129 
Table 3.2. IC50 for NADPH-DCPIP reductase reaction catalized by PfFNR. 
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3.1.1.2  SELECTIVITY OF INHIBITORS 
 
 
In vitro characterization of compounds selected by virtual screening allowed to identify 
five molecules, i.e. I8, I19, I21, I24 and I27, as good inhibitors of PfFNR. I evaluated their 
selectivity by measuring IC50 on homologue FNR of Toxoplasma gondii (TgFNR) and 
maize root (rFNR). I21 has been excluded from this analysis because this compound is 
known to be active against a variety of NAD(P)(H)-dependent oxidoreductases (Thompson 
D. C. et al., 1995).  
 
 
3.1.1.2.1   INHIBITION OF NADPH- K3Fe(CN)6 REDUCTASE REACTION OF TgFNR AND rFNR 
 
As shown in Table 3.3, I19 and I8 resulted to be highly specific for Apicomplexa FNRs. In 
particular, I8 is completely inactive against rFNR, while I24 and I27 are able to inhibit all 
FNRs tested. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50 K3Fe(CN)6    (µM) 
 PfFNR TgFNR rootFNR 
I8 47.1 ± 2.6 52 ± 1 - 
I19 10.8 ± 0.9 13.1 ± 0.8 221 ± 78 
I24 2.05 ± 0.04 0.59 ± 0.02 8.6 ± 0.4 
I27 9.6 ± 0.5 6.1 ± 0.4 12.6 ± 0.3 
Table 3.3. IC50 of PfFNR inhibitors for NADPH- K3Fe(CN)6 reductase reaction measured 
for homologous FNRs. 
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3.1.1.2.2  INHIBITION OF NADPH-DCPIP REDUCTASE REACTION OF     
TgFNR AND rFNR 
 
The effect of the inhibitors on NADPH-DCPIP reductase activity is similar to that 
observed with K3Fe(CN)6 as electron acceptor. Table 3.4 points out that I8 and I19 are 
good inhibitors of TgFNR but are poorly active against FNR from plant roots. Moreover 
I24 and I27 are selective for Apicomplexa FNRs also in case of DCPIP reductase activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IC50DCPIP    (µM) 
 PfFNR TgFNR rFNR 
I8 10.3 ± 0.2 7.6 ± 0.7 127.6 ± 5.7 
I19 1.8 ± 0.7 1.4 ± 0.2 190.9 ± 16.7 
I24 0.75 ± 0.02 0.47 ± 0.07 - 
I27 0.78 ± 0.03 0.62 ± 0.03 3.68 ± 0.06 
Table 3.4. IC50 of PfFNR inhibitors for NADPH- DCPIP reductase reaction 
measured  for homologous FNRs. 
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3.1.1.3  DETERMINATION OF INHIBITION CONSTANTS 
 
To further characterize the five best PfFNR inhibitors and to elucidate their mechanism of 
action, activity assays were performed by varying the concentration of both NADPH and 
inhibitor, using a mixed-inhibition model to fit the initial rate data.  
In Table 3.5 and 3.6 are reported kinetic parameters of PfFNR for both the diaphorase 
activities. Mixed inhibition is described by two inhibition constants (Ki and K’i). Ki 
(competitive inhibition constant) measures the effect of inhibitor on the apparent kcat/Km of 
the enzyme, while K’i (uncompetitive inhibition constant) measures the effect of inhibitor 
on the apparent kcat. For all the inhibitors considered, the inhibition mechanism showed 
that both the inhibition constants are statistically significant, making impossible to simplify 
the inhibition mechanism. Moreover, in each case, the two constants resulted to be 
significantly different among them, with Ki lower than K’i, thus excluding a pure non-
competitive inhibition pattern. 
In summary, all the compounds considered displayed a mixed-type inhibition mechanism, 
with a predominant competitive component with respect to NADPH.  
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NADPH-K3Fe(CN)6 reductase reaction 
 
kcat 
(e- eq s-1) 
KmNADPH 
(µM) 
Ki 
(µM) 
K’i 
(µM) 
kcat / KmNADPH 
(e- eq s-1 µM-1) 
I8 162.1 ± 4.4 39.8 ± 6.7 12.8 ± 3.7 99.8 ± 21.5 4.1 ± 0.7 
I19 159.9 ± 4.7 42.6 ± 7.1 3.6 ± 1.3 8.5 ± 1.1 4.02 ± 0.69 
I21 175.5 ± 6.8 41.1 ± 8.4 0.19 ± 0.09 0.42 ± 0.08 4.3 ± 0.9 
I24 189.9 ± 4.6 41.3 ± 5.2 0.33 ± 0.06 3.2 ± 0.5 4.6 ± 0.6 
I27 134.2 ± 3.1 31.6 ± 4.3 4 ± 1 11.1 ± 1.1 4.2 ± 0.6 
NADPH-DCPIP reductase reaction 
 
kcat 
(e- eq s-1) 
KmNADPH 
(µM) 
Ki 
(µM) 
K’i 
(µM) 
kcat / KmNADPH 
(e- eq s-1 µM-1) 
I8 68.7 ± 1.7 43 ± 6 16.3 ± 5.5 51.4 ± 9.2 1.6 ± 0.2 
I19 70.9 ± 1.6 42.5 ± 5.7 4.1 ± 1.1 13.9 ± 1.8 1.7 ± 0.2 
I21  27.4 ± 0.7 39.6  ± 5.5 0.028 ± 0.008 0.09  ± 0.01 0.7  ± 0.1 
I24 56.3 ± 1.3 29 ± 4 0.21 ± 0.05 1.2 ± 0.2 1.9 ± 0.3 
I27 68.22 ± 2.04 39.6 ± 6.5 1.4 ± 0.5 5.7 ± 1.1 1.7 ± 0.3 
Table 3.5. Inhibition kinetic parameters for the NADPH-K3Fe(CN)6 reductase reaction  
 
Table 3.6. Inhibition kinetic parameters for the NADPH-DCPIP reductase reaction  
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3.1.1.4  EFFECT OF QUINONIC INHIBITORS ON NADPH-CYTOCHROME c 
REDUCTASE REACTION OF PfFNR 
 
Reduced quinons are reactive towards molecular oxygen, being re-oxidated by it with 
generation of ROS. Cytochrome c (Cyt c) is sensitive to superoxide ion, in particular Cyt c 
is reduced by superoxide with an easily detectable raise of extinction coefficient at 550 nm. 
Moreover, in absence of the physiological substrate ferredoxin, FNRs possesses only a 
very weak NADPH-Cyt c reductase activity. For these reasons I considered the effect of 
quinonic inhibitors on this activity a good critirion to evaluate their capability to act as 
substrate of PfFNR. Figure 3.1A and 3.1B show the increase of Cyt c reductase activity of 
PfFNR as a function of I24 and I27 concentration. Altogether this results suggests that both 
I24 and I27 are probably reduced by PfFNR in presence of NADPH and rapidly reoxidized 
by O2, generating the superoxide anion.   
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Figure 3.1A and 3.1B. Effect of quinonic compounds I24 and I27 on NADPH-cyt c reductase 
reaction catalyzed by PfFNR. 
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3.1.2 PfFNR INHIBITION BY EBSELEN 
 
In order to identify inhibitors of PfFNR, I screened a library of compounds called 
Prestwick Chemical Library®, kindly provided by Prof. Pierfausto Seneci (Università degli 
Studi di Milano). The library contains 1200 small drug-like molecules, all commercially 
available. These compounds have been selected for their high chemical and 
pharmacological diversity as well as for their known bioavailability and safety in humans.  
I perform the screening by monitoring the NADPH-INT reductase activity of PfFNR 
because the reduction of INT gives an easily observable formation of a colored product. 
Using this activity assay, I identified ebselen ((2-phenyl-1,2-benzisoselenazol-3(2H)-one) 
as a powerful inhibitor of PfFNR activity. This compound is an anti-inflammatory seleno-
organic compound that has been extensively studied in the past. The particular interest in 
this molecule is due to its enzyme-like catalytic activity. In particular ebselen mimics 
glutathione peroxidase (GPx) activity by reducing a hydroperoxide at the expense of thiol 
group of a molecule like glutatione (Muller et al., 1984). 
Moreover ebselen reacts with thiol groups of proteins by forming a selenylsulphide bond 
and it has been reported to inhibit at low concentrations a variety of enzymes such as 
lipoxygenase, nitric oxide syntase, protein kinase C, NADPH-cytocrome P-450 reductase 
and NADPH oxidase (Schewe, 1995). Most of the enzymes inhibited by ebselen are 
involved in inflammatory and oxidative processes so it is reasonable to assume that the 
inibitory effect observed in vitro may contribute to the anti-inflammatory and anti-oxidant 
action of ebselen in vivo. Indeed, it has been demonstrated that ebselen is able to reduce 
oxidative stress arised after a cardiac ischemia (Maulik et al., 1998).  
Ebselen is a promising drug because of some characteristics such as low toxicity, high 
stability and also beacuse its selenium moiety is not liberated during biotrasformation and 
therefore it does not interfere with selenium metabolism of the organism. 
Several years ago it has been shown that ebselen possesses an antimalarial activity in vitro 
against chloroquine-resistant and chloroquine-sensitive P. falciparum strains in the asexual 
stages. Ebselen is able to block each stages of P. falciparum life cycle. Additionally this 
compound has no cytostatic or cytotoxic effects on human epatocytes indicating a selective 
inhibition of plasmodium (Hüter et al., 1989).  
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3.1.2.1  CHARACTERIZATION OF EBSELEN IRREVERSIBLE INHIBITION 
 
In order to evaluate the reversibility of ebselen action on the enzyme, PfFNR was 
incubated with ebselen and the residual catalytic activity at different incubation times was 
assayed after a dilution of 200-fold. Plots of residual activity versus time showed that the 
activity decayed untill a complete inhibition ensued after 10 min reaction (Figure 3.3). 
Moreover, ebselen removal by dilution did not result in any recovery of activity indicating 
an irreversible mechanism of inhibition. Same results were obtained measuring residual 
activity of the enzymatic variant PfFNR-C99A indicating that ebselen action does not 
involve enzyme dimerization (Figure 3.2). The addition of DTT or β-mercaptoethanol to 
the enzyme-inhibitor incubation mixture did not restore the catalytic activity strongly 
supporting the hypotesis of a non-reversible mechanism.  
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Figure 3.2. Residual activity of PfFNR-C99A evaluated after ebselen dilution 
Figure 3.3. Residual activity of wt PfFNR evaluated after ebselen dilution 
 58 
3.1.2.2  EFFECT OF REDUCED GLUTATHIONE ON PfFNR INACTIVATION BY 
EBSELEN 
 
Glutathione is a tripeptide containing glycine, cysteine and glutamate. The reduced form 
(GSH) is a strong intracellular antioxidant. In particular glutathione reduces disulfide bond 
between cytoplasmic proteins acting as electron donor. Moreover it reacts with peroxides 
(ROOH), generated by oxidative stress, converting them into alcohol and water (ROH + 
H2O). This reaction is catalyzed by glutathione peroxidase and it has been demonstrated 
that ebselen is able to mimic peroxidase activity reacting with GSH.  
In order to verify the hypotesis that ebselen could act on sulphydryl groups of PfFNR, I 
studied the capability of GSH to prevent the inactivation of the enzyme.  
PfFNR-C99A has been incubated with respectively 20, 40 and 60 µM of ebselen, either in 
the absence or in the presence of 100 µM GSH. As shown in the plots (Figure 3.4), GSH is 
able to protect PfFNR from inactivation suggesting indirectly that ebselen inhibits PfFNR 
acting on one or more cysteine residues which are important for enzyme activity or 
stability. 
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Figure 3.4. Effect of GSH on residual activity of PfFNR-C99A. 
Panel A: x = 20 µM ebselen 
Panel B: x = 40 µM ebselen 
Panel C: x = 60 µM ebselen 
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3.1.2.3  KINETICS OF EBSELEN INHIBITION OF PfFNR 
In order to study the inhibition mechanism of ebselen, I monitored the NADPH-dependent 
reduction of potassium ferricyanide in presence of different concentrations of inhibitor. 
The time courses of the reaction (Figure 4.5) were fitted with curves describing a slow 
onset of complete enzyme inhibition during the assay, according to a single exponential 
decay. The plots of each first-order rate constant (kobs) versus ebselen concentration (Figure 
4.6) allowed to calculated a second-order rate constant of PfFNR inactivation (kebselen) of 
2.06x10-3 µM-1 s-1. Since at a pH lower than 8 cysteine side chain should be protonated and 
less reactive, I evaluated PfFNR-C99A inhibition at pH 7.0 (Figure 4.6) yielding a 7-fold 
lower kebselen.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Effect of ebselen on the time course of NADPH-K3Fe(CN)6 reductase reaction 
catalyzed by PfFNR-C99A at pH 8.2 
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Figure 3.6. Secondary plot of the inactivation process showing the dependance of kobs by ebselen 
concentration either at pH 8.2 or pH 7. The slope of each interpolating line represents the second 
order constant (kebselen). 
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3.1.2.4  SENSITIVITY OF DIFFERENT FNRs TO EBSELEN 
In order to evaluate the specificity of ebselen, I studied its effect on wild type Spinacia 
oleracea (spinach) FNR (SoFNR), a plant homologue of PfFNR, and on Mycobacterium 
tuberculosis FprA, a ferredoxin reductase unrelated to PfFNR. As shown in Figure 4.7, 
FprA is completely resistant to ebselen. On the contrary SoFNR is inactivated by ebselen, 
although with a second order rate constant (kebselen) 10-fold lower than that of PfFNR 
(Figure 3.8 and Table 3.7). Moreover both PfFNR and SoFNR possesses in the active site a 
conserved cysteine residue, respectively Cys284 and Cys272, involved in the interaction 
with the substrate NADP(H). Interestingly the enzyme variant SoFNR-C272S is resistant 
to ebselen inactivation suggesting that Cys284 of PfFNR is possibly involved in the 
inactivation process. 
 
 
 
 
 
 
 
 
 
 
 
Time (s)
0 200 400 600 800
A4
20
 
n
m
0
0.2
0.4
0.6
0.8
1
0 µM ebselen
80 µM ebselen
FprA
Figure 3.7. Effect of ebselen on time course of NADPH-K3Fe(CN)6 reductase reaction  
catalyzed by FprA.  
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kebselen (s-1 µM-1) 
PfFNR-C99A 0.00206 ± 0.00006 
SoFNR 0.00022 ± 0.00002 
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Figure 3.8. Secondary plot of the inactivation process showing the dependance of kobs by 
ebselen concentration at pH 8.2 determined for PfFNR-C99A and SoFNR. The slope of 
each interpolating line represents the second order constant (kebselen). 
Table 3.7. Values of second order rate constant of inactivation. 
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3.1.2.5  PROTECTIVE EFFECT OF NADPH ON EBSELEN INACTIVATION  
The hypothesis of a potential involvement of Cys284 in ebselen inactivation process 
suggested to test if NADPH may protect PfFNR from inactivation. The reduction of 
ferricyanide by PfFNR-C99A was monitored in presence of ebselen at various NADPH 
concentrations. The secondary plot of the inactivation process clearly points out a partial 
protective effect of NADPH on PfFNR with respect to ebselen inactivation (Figure 3.9). 
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Figure 3.9. Secondary plot of the inactivation process showing the decrease of kobs  
at the increase of NADPH concentration.  
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3.1.2.6  EFFECT OF Cys284Ser SUBSTITUTION ON PfFNR INHIBITION  
In order to directly investigate the role of Cys284 of PfFNR on inactivation by ebselen, I 
purified the enzyme variant PfFNR-C99A/C284S. The substitution of Cys284 with a serine 
gave an enzyme with a residual activity sufficient to study its inactivation. As expected for 
the variant PfFNR-C99A/C284S, the activity measured as U/FAD (µmol product/µmol 
FAD/min) was about the 10% of that measured for the wild type enzyme (Table 3.8).  
 
 
 
 
 
 
At pH 8.2 the effect of the substitution Cys284Ser on ebselen inhibition resulted to be 
negligible whereas at pH 7 the second order rate constant (kebselen) of PfFNR-C99A/C284S 
inactivation is lower than that of PfFNR-C99A, even if only about 2-fold (Table 3.9).  
 
 
 
NADPH-K3Fe(CN)6 reductase activity 
                                                                         U/FAD 
wt PfFNR 5400 
PfFNR-C99A/C284S 400 
kebselen (s-1 µM-1) 
  pH 7 pH 8.2 
PfFNR-C99A 0.000294 ± 0.000009 0.002056 ± 0.000062 
PfFNR-C99A/C284S 0.000122 ± 0.00001 0.002359 ± 0.000033 
Table 3.8. Comparison between wt PfFNR and PfFNR-C99A/C284S activity. 
Table 3.9. Values of second order rate constant of inactivation 
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3.1.2.7  EFFECT OF EBSELEN ON FLAVIN FLUORESCENCE  
FAD is the prosthetic group of PfFNR and it is responsible of the enzyme spectral 
properties. Flavin fluorescence is measured as emission wavelength at 530 nm after an 
excitation at 450 nm and it is almost completely quenched by the interaction between 
apoenzyme and fluorophore. Figure 3.10 shows that the treatment of PfFNR-C99A with 
ebselen leads to dramatic increase of FAD fluorescence. Ultrafiltration of the enzyme 
treated with inhibitor for good showed that the increase in flavin fluorescence is due to the 
dissociation of flavin cofactor from the holoenzyme consistently with the irreversible 
inhibition mechanism of ebselen. Replacement of the active-site Cys284, a residue located 
in proximity of isoalloxazine ring of FAD, with a Ser made PfFNR much more resistant to 
ebselen-induced deflavinylation indicating that Cys284 is an important target of ebselen. A 
calculation of a rate constant for FAD dissociation was made impossible because of the 
complexity of fluorescence time courses. Nevertheless I deduced an half-life of the process 
by measuring the time required to obtain the release of 50% of FAD from enzyme (Table 
3.10). 
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Figure 3.10. Increase in FAD induced by ebselen. PfFNR-C99A was treated with 20 µM ebselen at pH 
8.2 (solid line) and PfFNR-C99A/C284S was treated with 20 µM ebselen at pH 8.2 (dashed line). 
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The comparison of 50% FAD time release with half-life of inactivation process (Table 
3.11) points out that the process of FAD release is slower than enzyme inactivation 
suggesting that ebselen inhibition mechanism consisting in two separate phases. A first 
step of inactivation consisting of a rapid modification of one or more cysteine residue 
followed by a second slower step in which the modification of further cysteines causes the 
alteration of enzyme tridimensional structure. As an alternative, a rapid modification of 
cysteine residues causes either enzyme inactivation or a destabilization of protein 
conformation leading to FAD release. Moreover the replacement of Cys284 with a Ser has 
only a poor effect on PfFNR inactivation but it has a dramatic effect in enzyme 
deflavinylation caused by ebselen. Indeed the dissociation process of prosthetic group of 
PfFNR-C99A/C284S is 10 fold slower than that of PfFNR-C99A.  
 
 
 
Time release of 50% of FAD  (s) 
  pH 7 pH 8.2 
Ebselen 10 µM 20 µM 10 µM 20 µM 
PfFNR-C99A 645 231 66 60 
PfFNR-C99A/C284S 1620 1224 840 693 
Half-life  (s) 
  pH 7 pH 8.2 
[Ebselen] 10 µM  20 µM  10 µM  20 µM  
     
PfFNR-C99A 240 ± 7 118 ± 4 34 ± 1 17 ± 0.5 
PfFNR-C99A/C284S 570 ± 47 290 ± 23 30 ± 0.4 15 ± 0.2 
Table 3.10. Kinetic parameters for the deflavinylation of different PfFNR forms. 
Table 3.11. Half-life of PfFNR inactivation process by ebselen.  
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3.1.2.8  EBSELEN TARGETS THE Cys RESIDUES OF PfFNR 
In order to evaluate the number of cysteine residues of PfFNR involved in the ebselen 
mechanism of action, I evaluated its effect on three variants of Plasmodium falciparum 
FNR: wild type PfFNR, PfFNR-C99A and PfFNR-C99A/C284S containing respectively 6, 
5 and 4 cysteine residues. I incubated the enzyme with different ebselen concentrations 
corresponding to an inhibitor/enzyme molar ratio between 0.5:1 and 10:1. Figure 3.11 
shows that the complete enzyme inactivation was obtained at a very low ebselen:enzyme 
molar ratio consistently with an irreversible mechanism of inhibition. Moreover the 
mutations that replaced either Cys99 (a known solvent-accesible residue) and Cys284 (a 
known residue involved in catalysis) decreased the molar ratio required to completely 
inactivate the enzyme indicating that both the residues Cys99 and Cys284 are targets of 
ebselen. The Figure 3.11 also suggests that, in addition to Cys99 and Cys284, at least two 
more Cys residues of PfFNR are targeted by ebselen.  
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Figure 3.11. Residual activity of different variants of PfFNR determined at the end-point  
of inactivation by different amounts of ebselen.  
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3.2 OVERPRODUCTION AND PURIFICATION OF PfFNR-C99A AS 
CLEAVABLE FUSION WITH SUMO PROTEIN 
In order to make easier in-depth studies on structure-function relationships in PfFNR, large 
amounts of recombinant protein are required. The expression and purification procedure 
previously developed (Balconi et al., 2009) is quite expensive because of the cost of the 
factor Xa required to generate the mature PfFNR forms. In order to eliminate the need of 
commercial proteolytic enzymes, I developed a new E. coli expression system for PfFNR, 
based on the fusion with the yeast SUMO protein (pET SUMO system, Invitrogen), which 
can be removed with a protease that can be easily produced in the laboratory in 
recombinant form. The plasmid pETSUMO-PfFNR-C99A was constructed and found to  
produce detectable amount of soluble recombinant protein in Rosetta (DE3) E. coli cells. 
As shown in Table 3.12, the specific activity in trasformed cells is significantly higher than 
in those untransformed. Moreover I observed the maximum value of specific activity after 
24 hours of induction. This result is confirmed by SDS-PAGE analysis which shows a 
similar improvement of the amount of protein with the highest expression level after 24 
hours of induction. (Figure 3.12).  
 
 
 Induction time 
(hrs) 
Protein/ml 
(mg/ml) 
Activity 
(U/ml) 
Specific activity 
(U/mg) 
3 h 15.5 12.7 0.82 
6 h 23.8 12.9 0.54 
21 h 26.7 15.8 0.59 
u
n
tr
a
n
sfo
rm
ed
 
24 h 24.6 13.9 0.57 
3 h 9.2 7.8 0.85 
6 h 11.5 9.2 0.80 
21 h 22 26.5 1.2 
tr
a
n
sfo
rm
ed
 
24 h 21.4 25.6 1.2 
Table 3.12. Expression of poly-His-SUMO-PfFNR-C99A in E. coli at 20 °C. Effect of induction time. 
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Since the protein contains an N-terminal tag of histidines, I isolated poly-His-SUMO-
PfFNR-C99A using a nickel-chelate chromatography as the initial purification step (Figure 
3.13A). Incubation with poly-His-Senp2 protease of partially purified poly-His-SUMO-
PfFNR-C99A resulted in a rapid cleavage to two fragments. A second purification step of 
nickel-chelate chromatography was performed in order to separate the protein from both 
protease and the residual uncleaved protein (Figure 3.13B). This second step was made 
possible by the affinity, altough weak, of the cleaved protein for the resin.  
 
 
Figure 3.12. Expression of poly-His-SUMO-PfFNR-C99A at 20 °C.  
SDS-PAGE analysis of soluble extracts of uintransformed (-) and transformed (+) cells with plasmid 
pETSUMO-PfFNR-C99A at different hours after induction with IPTG. Each sample contains 30 µg total 
proteins. Lane M, molecular mass markers (mass value are reported on the left). An asterisk is placed on the 
right of the band of poly-His-SUMO-PfFNR-C99A. 
M      3h       3h       6h      6h       21h     21h     24h    24h 
           -         +         -         +        -          +         -         + 
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Figure 3.13A and 3.13B. Chromatograms of the two separation steps of PfFNR-C99A purification. 
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It’s interesting to note that the first nickel-chelate chromatography also yielded, at low 
concentration of imidazole, a truncated form of the recombinant protein with a molecular 
weight not much different from that of PfFNR-C99A (Figure 3.14). On the basis of this 
observation I hypothesized that this protein could be generated by an in vivo partially 
spontaneous splitting of poly-His-SUMO-PfFNR-C99A. The hypothesis of an in vivo 
cleavage was supported by immunoblot analysis (Figure 3.15) with anti-PfFNR antibodies 
which indicates that shortened forms of the recombinant protein are produced in E. coli, 
possibly by proteolysis. The identity of this truncated protein and the integrity of the final 
product PfFNR-C99A have been verified by N-terminal sequencing. The major truncated 
protein resulted to lack of the two initial residues, Ser and Met, starting at Gly (-1), instead 
of the mature PfFNR-C99A which resulted to have the expected sequence starting at 
residue Ser (-3), indicating a proper cleavage of the fusion protein. The purification 
protocol yielded about 0.2 milligrams of PfFNR-C99A per gram of cells with a global 
yield of 28%. Table 3.13 and Figure 3.14 shows the achievement of PfFNR-C99A 
purification highly homogeneous and suitable for structural and functional 
characterization.  
 
 
 
 
 
 
 
 
 
 
Figure 3.14. SDS-PAGE analysis of PfFNR-C99A purification. 
Lane M, molecular mass markers; lane 1, soluble extract containing 30 µg total proteins; lane 2, poly-His-SUMO-
PfFNR-C99A after Ni Sepharose HP; lane 3, after buffer change by gel filtration; lane 4 after digestion with polyHis-
Senp2 protease (PfFNR-C99A cleaved is marked with an asterisk); lane 5, after the second chromatographic step on Ni 
Sepharose HP; lane 6, after buffer change by gel filtration; lane 7, PfFNR-C99A obtained by spontaneous proteolysis.  
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Step 
Volume 
(ml) 
Protein 
(mg) 
A280/A454 
FAD 
(nmoli) 
Activity 
(U)a 
Specific 
activity 
(U/mg) a 
Yield 
(%) 
Purification 
(fold) 
crude extract 180 2880 / / 6400 2.22 100 1 
Ni Sepharose 17.6 105 9.5 450 1660 15.8 26 7.12 
Ni Sepharose 4.75 11.7 6.9 323 1810 155 28 69.8 
Figure 3.15. Western blot immunostained using an anti-PfFNR antibody. Lane 1, analysis on soluble 
extracts (spontaneously cleaved PfFNR-C99A is marked with an asterisk). Lane 2, poly-His-SUMO-PfFNR-
C99A (marked with an asterisk); lane 3, spontaneously cleaved PfFNR-C99A (marked with an asterisk); lane 4, 
PfFNR-C99A. 
 
 
1        2      3      4 
* * 
* 
Table 3.13. Purification table of PfFNR-C99A. 
a NADPH-K3Fe(CN)6 reductase activity 
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3.3 PfFNR MUTANT FORMS 
In order to probe the role of His286 and Lys249 in the catalytic mechanism of PfFNR and 
in binding the substrate, I produced and characterized a series of mutant enzymes in which 
His286 was changed to Ala, Gln, Lys, or Leu, and Lys249 was replaced with Ala.  
3.3.1 PfFNR FORMS OVERPRODUCTION AND PURIFICATION 
Either the substitution of His286 with Ala, Gln, Lys and Leu or the substitution of Lys249 
with Ala yielded mutant PfFNR forms that were produced in E. coli Rosetta (DE3) and 
purified according to the protocol optimized for the wild type enzyme (Balconi et al., 
2009). His286 and Lys249 did not reveal a relevant role in protein folding and stability 
since each enzymatic variant were purified to an homogeneity and with a yield comparable 
to that of wild type PfFNR. Moreover mutations in His286 and Lys249 did not alter the 
ability of the enzyme to weakly bind to the nickel chelate resin after the removal of His-tag 
ruling out a role for His286 and Lys249 in determining the affinity for nickel ion. All the 
variants did not display differences in extinction coefficient and spectral features from 
those of wild type PfFNR, indicating that the engineered mutations do not perturb the 
conformation of the protein.  
 
3.3.2 CATALYTIC PROPERTIES OF His286 MUTANTS OF PfFNR 
The kinetic parameters of PfFNRs mutant forms have been determined for NADPH-
dependent diaphorase activities. As shown in Table 3.14, the effect of the mutations on the 
steady-state kinetic parameters for the NADPH-K3Fe(CN)6 reductase reaction is strongly 
dependent on which residue is replacing His286. With the exception of the His286Gln 
replacement, which slightly increases kcat, all the other mutations significantly decrease 
both kcat/KmNADPH and kcat. The interpretation of these data is made difficult because 
ferricyanide ion, besides being an artificial substrate, is a competitive inhibitor of PfFNR 
with respect to NADPH. Then I have also determined the kinetic parameters using the 
artificial electron acceptor DCPIP, which does not inhibit PfFNR. The kinetic properties of 
PfFNR mutants measured with DCPIP are in good agreement with those observed using 
ferricyanide (Table 3.15). Notably, in the NADPH-DCPIP reductase reaction, the mutation 
His286Gln, besides slightly increasing kcat, strongly increases kcat/KmNADPH. Moreover all 
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the other aminoacid substitutions negatively affect both kcat/KmNADPH and kcat (Table 3.15). 
Unexpectedly, steady-state kinetics indicated that the His286Leu mutation determines the 
largest decrease in kcat/KmNADPH, while mutation His286Lys yields the mutant enzyme with 
the lowest kcat when ferricyanide is the electron acceptor (Table 3.14). This evidence 
demonstrates that Leu, a residue commonly found at this site in other plastidic-type FNRs, 
and Lys, which carries a positive charge suitable for the interaction with NADP(H) 
pyrophosphate, are not substitutes for His286 in PfFNR. 2’-P-AMP acts on PfFNR forms 
as competitive inhibitor with the substrate NADPH. I evaluated the role of His286 side 
chain in binding the adenylate moiety of the substrate by measuring the inhibition constant 
displayed by 2’-P-AMP (Ki2’-P-AMP). Ki2’-P-AMP values can be taken as a rough estimate of 
the dissociation constant of the complexes between the PfFNR forms and the inhibitor. 
Table 3.16 shows that the values of Ki2’-P-AMP of the mutant PfFNRs well compare with 
those of KmNADPH in the diaphorase reactions (Table 3.14 and 3.15). PfFNR-H286A shows 
the lowest affinity for the ligand, while PfFNR-H286Q is the form most similar to the 
wild-type enzyme. Interestingly, PfFNR-H286K displays an affinity for 2’-P-AMP 8-fold 
higher than that of the wild-type PfFNR. 
 
Table 3.14. Kinetic parameters of PfFNR forms in the NADPH-K3Fe(CN)6 reductase 
reaction  
 kcat KmNADPH kcat/ KmNADPH KiK3Fe(CN)6 
PfFNR form (e- equiv s-1) (%) (µM) (e- equiv s-1 µM-1) (%) (µM) 
wild type 250 ± 8 (100) 36 ± 6 7.0 ± 1 (100) 230 ± 40 
H286Q 370 ± 6 (150) 57 ± 5 6.5 ± 0.6 (93) 110 ± 11 
H286K 7.6 ± 0.4 (3) nda nda nda 
H286A 89 ± 2 (36) 520 ± 55 0.17 ± 0.01 (2.4) 91 ± 11 
H286L 15 ± 0.6 (6) 370 ± 46 0.04 ± 0.005 (0.6) 91 ± 15 
aNot determinable. A reliable estimate of KmNADPH was not possible because of the 
apparently very low value of KiK3Fe(CN)6 for the PfFNR-H286K mutant.  
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Table 3.15. Kinetic parameters of PfFNR forms in the NADPH-DCPIP reductase 
reaction  
 kcat KmNADPH kcat/ KmNADPH 
PfFNR form (e- equiv s-1) (%) (µM) (e- equiv s-1 µM-1) (%) 
wild type 110 ± 3 (100) 71 ± 4 1.5 ± 0.1 (100) 
H286Q 140 ± 11 (130) 22 ± 3 6.3 ± 0.9 (420) 
H286K 12.0 ± 0.7 (11) 140 ± 14 0.09 ± 0.001 (5.8) 
H286A 35.0 ± 1.7 (32) 400 ± 40 0.098 ± 0.009 (6.5) 
H286L nda nda nda 
aNot determinable. The kinetic parameters were not measured because of an anomalous 
reactivity of PfFNR-H286L with DCPIP. 
 
 
 
Table 3.16. Parameters for the inhibition by 2’-P-AMP of the PfFNR forms in the 
NADPH-DCPIP reductase reaction a 
 Ki2’-P-AMP 
PfFNR form (µM) 
wild type 24 ± 2 
H286Q 71 ± 7 
H286K 2.9 ± 0.2 
H286A 230 ± 25 
a
 The Ki2’-P-AMP of PfFNR-H286L was not determined because of an anomalous reactivity 
of this mutant enzyme with DCPIP.  
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3.3.3 BINDING OF NADP+ 
In order to further investigate the role of His286 in the stabilization of the enzyme-
substrate complex, I studied the interaction of the PfFNR forms with NADP+ by 
differential spectrophotometry. It is known that NADP+ binding to plastidic-type FNR 
induces perturbation in the visible region of the protein-bound FAD spectrum. 
Furthermore, it has been demonstrated that the positive peak around 500 nm in the 
difference spectrum (Figure 3.16B) is due to the stacking interaction between the 
nicotinamide of NADP+ and the isoalloxazine ring of FAD ( Piubelli et al., 2000). Thus 
this experiment provides both the information about the Kd for NADP+ and the position of 
its nicotinamide ring within the complex. The Kd values of the NADP+ complexes are 
comparable with the Ki of 2’-P-AMP, showing similar trends. Figure 3.16A shows the 
titration curves of PfFNR forms with NADP+ indicating the fraction of bound enzyme 
versus the relative concentration of NADP+. The difference spectra in the visible region of 
the NADP+-saturated PfFNR forms are markedly different from that of the wild-type 
enzyme (Figure 3.16B). In PfFNR-H286Q, the positive peak centered at 504 nm is much 
more intense than that observed with PfFNR. On the other hand, substitutions of His286 
with Ala and Lys led to enzyme forms whose NADP+-complexes displayed a negative 
peak at this wavelength. These observations indicates that the positioning of the 
nicotinamide ring of NADP+ in proximity to the isoalloxazine ring of FAD is stronlgy 
impaired by substitutions in Ala and Lys, whereas is stabilized by substitution in Gln. This 
conclusion is also supported by the values of kcat since the stacking interaction 
nicotinamide-isoalloxazine is an essential requirement for the HT. Only for the mutant 
PfFNR-H286K the increase of the affinity for NADP+ is related to a destabilized 
interaction between nicotinamide of NADP+ and isoalloxazine ring of FAD. 
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Table 3.17. Parameters for Kd values of the complexes between PfFNR and NADP+ a 
 KdNADP+ 
PfFNR form (µM) 
wild type 60 ± 9 
H286Q 130 ± 10 
H286K 30 ± 5 
H286A 280 ± 90 
a
 The very small spectral changes induced by binding of NADP+ to PfFNR-H286L 
prevented a reliable estimate of the Kd value of the resulting complex. 
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Figure 3.16 A. Complex formation between PfFNR forms and NADP+. Titration curves obtained by 
successive additions of NADP+ to solutions of wild-type PfFNR, PfFNR-H286K, PfFNR-H286Q and 
PfFNR-H286A at 15 °C. PfFNR forms were diluted in 50 mM Tris-HCl, pH 7.6.Curves represent the 
theoretical eqution for 1:1 protein-ligand binding model drawn using Kd and ∆ε parameters obtained by 
nonlinear fitting of experimental data as described in Materials and Methods section 2.9. B. Difference spectra 
of enzyme-NADP+ complexes. Difference spectra of the complexes of wild-type PfFNR are extrapolated at 
infinite NADP+ concentration. 
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3.3.4 PHOTOREDUCTION EXPERIMENTS 
 
Photoreduction experiments under anaerobic conditions provide informations about the 
spectral properties of the flavin prosthetic group in its various redox states. Nicotinamide-
flavin stacking interactions can be easily detected by the appearence of absorption bands 
above 600 nm, which are due to the formation of charge-transfer complexes between 
NADPH and FAD (CT1) and between NADP+ and FADH- (CT2).  
In order to verify if the change of His286 hampers or favors the HT-competent position of 
the nicotinamide, I performed stepwise anaerobic photoreductions of PfFNR-H286Q and 
PfFNR-H286K in presence of NADP+. As in the case of wt PfFNR, the peak at 454 nm of 
bound FAD becomes almost completely bleached in mutant PfFNRs before NADPH starts 
to accumulate, as evaluated by the increase in absorbance at 340 nm. In the case of wt 
PfFNR a CT complex, most probably CT2, is clearly observed in the latest stages of 
photoreduction (Figure 3.17 A). In the case of PfFNR-H286Q the amount of CT was 
slightly but significantly higher (Figure 3.17 B). Conversely, CT absorption bands were 
not detected in PfFNR-H286K (Figure 3.17 C). These results confirm that the His286Gln 
mutation stbilizes the interaction between the redox-active moieties of bound NADP(H) 
and FAD, which is, instead impaired by the His286Lys mutation.  
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Figure 3.17. Photoreduction in presence of NADP+. Absorbance spectra of anaerobic solutions of ~15 µM 
PfFNR (A), PfFNR-H286Q (B), and PfFNR-H286K (C) with 18 µM NADP+ in 50 mM HEPES-NaOH, pH 7.0 
containing 10% glycerol, recorded before (thin solid line) and after successive periods of illumination (1, 3, 5 
and 12 min) with visible light. Arrows indicate the direction of the spectral changes.  
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3.3.5 RAPID REACTION STUDY OF THE REDUCTIVE HALF REACTION OF 
PfFNR-H286Q AND PfFNR-H286L WITH NADPH 
 
In order to have a further proof of the effect of His286 replacement on HT from NADPH 
to FAD, two selected mutants, PfFNR-H286Q and PfFNR-H286L, were reacted at 25 °C 
with NADPH at concentration ranging from 25 µM to 1000 µM in comparison with wild-
type enzyme. Absorbance data were collected over the entire 400-700 wavelength span of 
the diode-array detector. The composition of the reaction medium (50 mM HEPES-NaOH, 
pH 7.0) is different from that used for the steady-state parameters determination and this 
composition was chosen to allow a comparison with the recently obtained data for wild-
type PfFNR. The time course of the reaction of the wild-type enzyme with 500 µM 
NADPH (after mixing) is shown in Figure 3.18A and 3.19A,B. Within the instrument 
dead-time, the transient formation of CT1 between NADPH and enzyme bound FAD 
occured, as judged from the high absorbance above 500 nm of the spectra recorded 
immediately after mixing, and from the value of absorbance at 454 nm, lower than 
expected for oxidized PfFNR (Figure 3.18A). The observable part of the reaction consisted 
in a further bleaching of the flavin main absorbance peak with a concomitant decrease of 
the absorbance band above 500 nm. The reaction of wild-type PfFNR with NADPH was 
previously described as a single-phase process with a rate constant essentially independent 
of NADPH concentration (Balconi E. et al., 2009). Here I performed a more detailed 
analysis by extending the reaction time of > 100 ms, allowing the observation of two 
phases. I found a first phase with a kobs1 of ~150 s-1, in which most of the absorption at 454 
nm was lost corresponding to the HT step of the catalytic cycle. The process is followed by 
a second slower phase with a kobs (kobs2) of 8 s-1, which accounts for ~10% of the total A454 
change (Figure 3.18A and 3.19A). As expected on the basis of its higher kcat values, 
PfFNR-H286Q was found to react with NADPH faster than the wild-type enzyme (Figure 
3.18B and 3.19A). While the rate constant of the slow phase is essentially unchanged with 
respect to that of the wild-type enzyme, the kobs1 was found to be 240 s-1, a value 1.7-fold 
higher than that of wt PfFNR (Figure 3.19C). Although more than half of the first fast 
phase occured in the dead time, the first spectra recorded 0.7 ms after mixing shows a 
broad band of absorbance above 500 nm which can be attribute to CT complexes and 
which is more intense than that recorded in the case e of the wild-type enzyme (Figure 
3.18A and 3.18B). This observation suggests that the initial enzyme-NADPH complex has 
an higher CT character in the PfFNR-H286Q than in the wild-type enzyme, which most 
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probably represents the cause of the higher HT rate of the mutant PfFNR form. The 
reduction of the PfFNR-H286L differed from that of the wild-type PfFNR in three aspects. 
First, the fast phase of FAD bleaching occurs with a kobs1 of 44 s-1, a value significantly 
slower than that of wt PfFNR, and, consistently with this low HT rate, the amount of CT 
complexes observed immediately after mixing was smaller (Figure 3.18 C). Second, the 
slower phase of the reaction with NADPH, although occurs with a rate similar to that of 
other PfFNR forms, accounts for ~50% of the total A454 change for NADPH concentrations 
> 100 µM (Figure 3.18C and 3.19C). The amplitude of slow phase was found to decrease 
as the NADPH concentration increasing, while that of the first phase was found to 
increase. In order to provide an explanation for this behavior, I proposed that the 
equilibrium between CT1 and CT2 is altered in PfFNR-H286L with respect to the wt 
enzyme, leaving a significant fraction of bound FAD in the oxidized form at the end of the 
first observable phase. Moreover, the spectral features of the species accumulating during 
the slow phase suggests the presence of blue semiquinone form of the flavin (Figure 
3.18C) indicating that in this part of the process a reaction takes place between oxidized 
and reduced enzyme forms to yield the semiquinone species of bound FAD. Third, as 
shown in Figure 3.19C, the value of kobs1 displays a dependence on the NADPH 
concentration that is more marked than that observed with the two other enzyme forms, 
consistent with the higher values of KmNADPH of PfFNR-H2386L.  
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Figure 3.18. Spectra recorded by stopped-flow during the anaerobic reduction of PfFNR forms (17-18 µM) by 
500 µM NADPH (after mixing) at 25 °C in 50 mM HEPES-NaOH pH 7.0.  
A Spectrum of oxidized PfFNR (black) and those recorded 1 ms (dark green), 2 ms (red), 5 ms (light green), 7 ms 
(blue), 11 ms (magenta), 17 ms (brown), 61 ms (aqua) and 1 s (olive) after mixing.  
B Spectrum of oxidized PfFNR-H286Q (black) and those recorded 0.7 ms (dark green), 2.2 ms (red), 3.7 ms (light 
green), 6.7 ms (blue), 11 ms (magenta), 32 ms (brown), 110 ms (aqua) and 450 ms (olive) after mixing.  
C Spectrum of oxidized PfFNR-H286L (black) and those recorded 2.2 ms (dark green), 6.7 ms (red), 14 ms (light 
green), 29 ms (blue), 76 ms (magenta), 320 ms (brown), 1 s (aqua) and 2.9 s (olive) after mixing.  
 84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19. Absorbance traces and NADPH concentration dependence of the reductive half-reaction of 
selected His286 mutants of PfFNR, as studied by stopped-flow spectrophotometry. The PfFNR forms were 
reacted with NADPH at concentrations ranging from 25 µM to 1 mM (after mixing).  
A. Absorbance at 454 nm recorded during the reaction of PfFNR (black). PfFNR-H286Q (magenta), and PfFNR-
H286L (blue) with 500 µM NADPH. 
B. Absorbance at 700 nm of the same reactions displayed in panel A. 
C. Plot of the value of the rate constant of the fast phase of the reaction as a function of NADPH concentration (after 
mixing). Data from the three enzyme forms are identified by the same colors as those used in panels A and B. Fitting 
curves rectangular hyperbolae. Limiting values are 148 ± 2, 240 ± 4, and 44 ± 0.9 s-1 for wt PfFNR, PfFNR-H286Q 
and PfFNR-H286L, respectively. 
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3.3.6 pH DEPENDENCE OF kcat and kcat/KmNADPH 
 
The pH dependence of the steady-state kinetic parameters of wild-type PfFNR were 
determined in the pH range 6.25-10.25, at varying concentrations of both NADPH and 
K3Fe(CN)6. The kcat value is pH independent between pH 6.25 and 9.5, suggesting that 
there are not ionizable catalytic groups required for catalysis in this range of pH (Figure 
3.20). Instead, the data about kcat/KmNADPH values were fit with the equation describing a 
pH profile with an upper limiting value at low pH and a slope of -2, consisting with the 
requirement of two protonated groups important either for binding or catalysis (Figure 
3.20). The apparent pKa value determined for both the groups was 9.5 ± 0.04. In order to 
evaluate if His286 could be one of the ionizable groups responsible of the pH effect, I 
performed the pH profiles of the kinetic parameters with PfFNR-H286Q (Figure 3.21). The 
kcat value is pH independent between pH 6.25 and 9.5 as well as previously determined for 
wild-type enzyme. Instead, the kcat/KmNADPH values of PfFNR-H286Q were fit best with an 
equation describing a pH profile with an upper limiting value at low pH and a slope of -1. 
The apparent pKa determined for the plot of kcat/KmNADPH versus pH was 8.5 ± 0.01. This 
result indicates that His286 is most likely one of the two ionazable groups that is 
responsible for substrate binding in the wt enzyme, but not for catalysis since the kcat is pH 
independent throughout all the pH investigated.  
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Figure 3.20. pH dependence of the kcat and kcat/KmNADPH values for wild-type PfFNR. Activity assays was 
measured at varying concentration of both NADPH and K3Fe(CN)6 between pH 6.25 and 10.25, at 25 °C.  
Figure 3.21. pH dependence of the kcat and kcat/KmNADPH values for PfFNR-H286Q. Activity assays was 
measured at varying concentration of both NADPH and K3Fe(CN)6 between pH 6.25 and 10, at 25 °C.  
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3.3.7 STRUCTURAL CHARACTERIZATION OF PfFNR-H286K AND PfFNR-H286L 
 
Crystallization of PfFNR-H286L, PfFNR-H286L-2’P-AMP complex and PfFNR-H286K-
2’-P-AMP was carried out in collaboration with Dr. Mario Milani, Università degli Studi 
di Milano, Milan, Italy. We obtained crystals that displayed overall structures very similar 
to their wild-type analogues obtained in absence and in presence of 2’-P-AMP (Milani M. 
et al., 2007). It’s known that PfNR undergoes an helix-coil transition upon 2’-P-AMP 
binding. In particular, α-helix F is shortened by two turns at its N-terminus, while the loop 
included between α-helix F and β-sheet 9 is correspodingly elongated by seven residues 
(Figure 3.22). Such a conformational changes induced by 2’-P-AMP binding have been 
never found in other FNRs. The same behavior has been observed in PfFNR-H286L. 
Interestingly, in the case of PfFNR-H286L, ligand binding was obtained only after addition 
of a concentration of 2’-P-AMP 3-fold higher than that required for the wild-type enzyme, 
consisting with the decreased affinity of this mutant for the NADP+ analogue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22. Superimposition of PfFNR (yellow) and PfFNR-2’-P-AMP complex (blue). In the circle is 
highlighted the helix-coil transition upon 2’-P-AMP binding. 
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On the other hand, in a manner consistent with its high affinity for the ligand (Table 3.16 
and 3.17), PfFNR-H286K was easily crystallized in presence of 2’-P-AMP. Since mutation 
of His286 affects the affinity for 2’-P-AMP, we focused our attention on the 2’-P-AMP 
binding site in order to explain the possible correlations between functional and structural 
aspects. In the PfFNR-H286L-2’-P-AMP crystal structure the mutation mainly affect the 
binding mode of 2’-P-AMP, causing a displacement if its adenine end toward Tyr258, 
which in turn adjusts its position (Figure 3.23). Indeed the presence of Leu286 residue 
causes the loss of a stacking interaction between 2’-P-AMP and the protein, promoting a 
small sliding of the ligand toward the protein surface. In the case of PfFNR-H286K a 
displacement of Lys side chain occurs, likely due to the longer Lys side chain compared to 
His (Figure 3.23). Moreover this displacement could contribute to the destabilization of the 
nicotinamide-flavin interaction and thus be partially responsible for the low kcat values of 
this mutant form (Table 3.14 and 3.15). Lys286 can also establish an electrostatic 
interaction with the carboxy terminus of Tyr316 that could restrict its mobility. Since 
displacement of the C-terminal Tyr is important for the accesibility of the nicotinamide 
ring of NADPH to the isoalloxazine ring of FAD, this interaction might concur to hamper 
the catalytic activity of PfFNR-H286K. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23. Binding of 2’-P-AMP to wild-type and mutant PfFNR forms. 2’-P-AMP complexes of PfFNR-
H286K (red) and PfFNR-H286L (blue) superposed with that of wild-type PfFNR (yellow). The two arrows 
indicate the direction of sliding of the adenine ring in the Leu mutant (blue) and displacement of 5’-phosphate in 
the Lys mutant (red).  
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3.3.8 FUNCTIONAL CHARACTERIZATION OF PfFNR-K249A 
 
In order to evaluate the possible role of Lys249 in NADPH recognition, I characterized the 
PfFNR-K249A mutant form. For both NADPH-K3Fe(CN)6 and NADPH-DCPIP reductase 
activity the kcat values of this mutant are not significantly affected ( 220 ± 5 and 110 ± 6 e- 
equiv s-1, respectively). On the contrary the kcat/KmNADPH values in the ferricyanide 
reductase reaction (0.73 ± 0.07 e- equiv s-1 M-1) was found to be 10-fold lower in 
comparison to that of the wild-type enzyme. The kcat/KmNADPH ratio measured with DCPIP 
as substrate is only slightly affected by the Lys249Ala mutation (1.0 ± 0.13 e- equiv s -1    
M-1). To probe the affinity of NADP(H)-binding site for its ligands, the interaction bof 
PfFNR-K249A with 2’-P-AMP and NADP+ was investigated by inhibition and titration 
studies, under the same condition used for His286 mutants. The Ki2’-P-AMP and KdNADP+ 
were found to be 5.4- and 8.3-fold higher compared to the wild-type enzyme, respectively. 
The difference absorption spectrum of the PfFNR-K249A-NADP+ complex was found to 
be very similar to that of the complex with wt PfFNR. It’s to notice that kcat/KmNADH ratio 
of the mutant enzyme in the ferricyanide reductase reaction (0.13 ± 0.02 e- equiv s -1 M-1) is 
not differ from that of the wild-type enzyme, ruling out the possibility that the Lys249 side 
chain interacts with groups other than the 2’-phosphate of the substrate nucleotide. 
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DISCUSSION 
 
 Malaria is still today one of the most important infectious disease in the world, 
primarily due to the increasing resistance of Plasmodium spp. to available drugs. Indeed, 
new drugs against malaria parasites are urgently needed. Since FNR of Plasmodium 
falciparum (PfFNR) is a promising novel target for antimalarial therapies, I decided to look 
for inhibitors of PfFNR using the approach of library screening. 
 The results I have obtained show that in silico screening of virtual library is a good 
strategy to identify inhibitors of PfFNR. 16 compounds to which the program attributed the 
best score were taken into account for further analysis. In particular I determined their IC50 
by measuring two different diaphorase activity. Four of these compounds, I19, I21, I24 and 
I27 turned out to be powerful inhibitors of PfFNR with an IC50 lower than 10 µM in the 
case of NADPH-K3Fe(CN)6 reductase activity, and lower than 2 µM in the case of 
NADPH-DCPIP reductase activity. I8 resulted to be sligthly less powerful with an IC50 
value of about 10 µM for NADPH-DCPIP reductase activity. It should be noted that the 
diaphorase activity with DCPIP is the most sensitive to inhibition, probably because 
ferricyanide, which acts also as PfFNR inhibitor, could interfere with the interaction 
enzyme/inhibitor. Some of these inhibitors, I8 and I19, showed to be highly selective for 
Apicomplexa FNRs. I8 inhibits more efficiently Toxoplasma gondii FNR with respect to 
Plasmodium falciparum FNR, whereas I24 and I27 resulted to inhibit also maize root FNR. 
I21 compound is a known unselective inhibitor capable to inhibit a variety of 
NAD(H)/NADP(H)-dependent oxidoreductase. Steady-state kinetic analysis indicated that, 
for all the inhibitors considered, the inhibition mechanism is mixed. Unlike to that 
expected from the virtual library screening, the selected inhibitors doesn’t act purely by 
competing with NADPH. However the comparison of Ki and K’i indicates that, for all the 
compounds considered, the competitive inhibition component, affecting apparent kcat/Km, is 
predominant with respect to the that uncompetitive which affects apparent kcat. Finally, the 
quinonic I24 turned out to act as PfFNR substrate, being rapidly oxidized from molecular 
oxygen with production of superoxide radical. 
 The screening of Prestwick Chemical Library, performed by monitoring the 
NADPH-INT reductase activity of PfFNR, revealed that ebselen is active against PfFNR 
by acting as powerful irreversible inhibitor. For the characterization of ebselen mechanism 
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of action I used the enzymatic variant PfFNR-C99A which shares the same catalytic 
features with the wild-type form but it doesn’t undergo dimerization and inactivation, 
simplifying the interpretation of results. Ebselen is able to inactivate PfFNR-C99A with a 
second order kinetic in which the rate of the process is proportional to both enzyme and 
inhibitor concentration, excluding a formation of reversible enzyme/inhibitor complex. 
Since ebselen is known to react with thiol groups by forming a selenylsulphide bond, I 
hypothesized that inactivation could involve Cys residues of the enzyme. For this reason I 
measured the second-order rate constant (kebselen) either at pH 8.2 or pH 7.0. Inactivation 
constant resulted 7-fold higher at pH 8.2 than pH 7.0 consistently with Cys side chain pKa 
value of about 8. PfFNR turned out to be very sensitive to ebselen in comparison to other 
homologous and non-homologous FNRs. In particular Spinacia oleracea (spinach) FNR 
(SoFNR), a plant homologue of PfFNR, showed a kebselen 9-fold lower than that observed 
for PfFNR-C99A, while Mycobacterium tuberculosis FprA, a ferredoxin reductase 
unrelated to PfFNR, is completely resistant to ebselen inhibition. The different PfFNR, 
SoFNR and FprA susceptibility to ebselen action suggested that a possible target of the 
inhibitor could be an active-site Cys, a peculiar residue of plant-like FNRs. In order to test 
this hypothesis, I studied the enzymatic variant SoFNR-C272S, already available in the 
laboratory, and PfFNR-C99A-C284S. SoFNR-C272S is resistant to ebselen, whereas 
PfFNR-C99A-C284S has a kebselen similar to the PfFNR-C99A at pH 8.2 but 2-fold lower at 
pH 7.0. Effect of ebselen on PfFNR conformation have been studied by spectrofluorimetry. 
Enzyme-bound FAD fluorescence is quenched by the interaction between apoenzyme and 
fluorophore. The treatment of PfFNR-C99A with ebselen leads to a dramatic increase of 
FAD fluorescence indicating the dissociation of the flavin cofactor from holoenzyme. A 
calculation of a rate constant for FAD dissociation was made impossible because of the 
complexity of fluorescence time course. Nevertheless, by comparing time needed to 
release 50% of bound-FAD and half-life of inactivation process, the inactivation of 
PfFNR-C99A is faster than FAD release. This observation could be explained 
hypothesizing that a rapid modification of PfFNR, which causes inactivation, also 
destabilizes the native conformation, making the enzyme releasing FAD (with a slower 
kinetic). According to another hypothesis, the rapid modification of one or more Cys 
residues causes the loss of activity and it is followed by a slower modification of other Cys 
residues concomitantly to FAD release. It has been also investigated the effect of 
Cys284Ser mutation on FAD release promoted by ebselen. The mutation effectively slows 
down FAD dissociation either at pH 8.2 or pH 7.0. Differently from SoFNR, modification 
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of Cys284 of PfFNR seems to have a predominant role in FAD release process rather than 
in inactivation, suggesting that effectively FAD release and inactivation involve the 
modification of different Cys residues. This idea is supported also by the fact that ebselen 
targets two other Cys residues of PfFNR besides Cys99 and Cys284. The mechanism of 
ebselen inhibition resulted from this analysis could explain the inhibitory effect described 
also for enzymes related to plant-like FNRs, as NADPH-oxidase, cytochrome P450 
reductase and NO syntase. As a matter of fact, all of these enzymes possess a conserved 
active-site Cys which could represent the target of ebselen action. 
 In 2007, the crystal structure of PfFNR has been solved as in free form and in 
complex with the substrate analogue 2’-P-AMP. The structure revealed that the enzyme 
binds the substrate in an unusual way respect to other FNRs. In particular (i) substrate 
binding is associated to a substantial conformational change of the binding-site, (ii) 
positively charged side chains interacting with 2’-phosphate group of 2’-P-AMP are 
lacking, (iii) His286, a residue not conserved in other FNRs in which is substituted with an 
aliphatic residue (Leu), could substantially contribute in the binding of both the adenilic 
portion and the 5’-phosphate group of the substrate.  
 Aim of this work is to investigate the role in catalysis of two basic residues, His286 
and Lys249, located in the NADP(H)-binding site of PfFNR and far from the site where 
the hydride transfer (HT) between substrate and FAD bound to the enzyme occurs. In 
plant-like FNRs catalysis of HT occurs in two steps: first, the conversion of the ground 
state of NADPH in the Michaelis complex, where the nicotinamide portion of the substrate 
is disordered and second, the conversion to a transition state where the nicotinamide stacks 
onto the flavin ring according to a precise geometry. The replacement of these two residues 
will not affect directly the HT, rather they can influence the reductive half-reaction in two 
possible ways: (i) by altering the affinity for NADP(H) affecting kcat/KmNADPH or (ii) by 
altering the orientation of nicotinamide moiety of NADP(H) affecting kcat. 
The replacement of His286 resulted in a complex effects depending on the replacement 
residue. Deletion of the imidazole group by the His286Ala mutation significantly decreases 
kcat/KmNADPH by 15-40-fold, depending on the the electron acceptor used, and also kcat is 
lowered to one-third of that of the wild-type enzyme. Thus, His286 seems to play a critical 
role not only in NADP(H) binding but also in orienting the nicotinamide portion of the 
bound substrate to favor HT to FAD. This conclusion is supported by 2’-P-AMP inhibition 
and by NADP+ binding studies, where a 5-10-fold decreasing in affinity was observed. 
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Unexpectedly, replacement of His286 with Leu impaired the catalytic activity of PfFNR to 
an even greater extent than the mutation to Ala. The crystal structure of the complex 
PfFNR-H286L-2’-P-AMP showed a significant shift of the position of bound analogue 
which could explain the destabilization of the HT-competent conformation of the 
nicotinamide moiety. Moreover rapid kinetics studies attest that in this enzyme form the 
CT complexes  are destabilized and HT proceeds at a rate 3.4-fold lower than in the wild-
type enzyme.  
Such results remark the notion that the imidazole ring of His286 establishes with 
NADP(H) critical contact for catalysis, which an aliphatic group cannot form.  
Surprisingly, the substitution of His286 with Lys led to the lowest kcat. Since PfFNR-
H286K resulted to bind 2’-P-AMP and NADP+ with high affinity, I concluded that this 
mutation specifically destabilized the HT-competent conformation of NADP(H) in the 
transition state. The crystal structure of the complex PfFNR-H286K-2’-P-AMP suggested 
that this effect could be due to a slight displacement of the pyrophosphate group of bound 
NADP(H), which can be transmitted to the nicotinamide moiety.  
Replacement of His286 with a Gln resulted in an enzyme form that was highly active and 
mantained ligand binding properties similar to those of the wild-type enzyme. PfFNR-
H286Q displays a kcat significantly higher than that of PfFNR, due to a 1.6-fold increase in 
the HT rate, as shown by stopped-flow experiments. NADP+ binding induced more intense 
spectral perturbations when bound to PfFNR-H286Q than to PfFNR, and a greater amount 
of CT species were observed in the case of this mutant form with respect to PfFNR during 
enzyme photoreduction in the presence of NADP+ and during enzyme reaction with 
NADPH, as studied by rapid mixing. These observations indicate that the higher kcat values 
of PfFNR-H286Q are due to a better stabilization provided by Gln, compared to His, of the 
HT-competent conformation of NADPH.  
I have replaced also Lys249, a residue located in the NADP(H) adenylate-binding loop of 
PfFNR. The crystal structure of PfFNR-2’-P-AMP did not highlight interactions between 
this residue and the ligand (Milani et al., 2007). However, I argued that Lys249 would be 
sufficient flexible in solution to let its side chain reach the 2’-phosphate of the bound 
substrate. As a matter of fact, the Lys249Ala substitution resulted in a 10-fold decrease in 
kcat/KmNADPH with no effect on the kcat of the ferricyanide reductase reaction. The role of 
Lys249 in binding NADP(H) was confirmed also by 2’-P-AMP inhibition and NADP+ 
binding sudies. The slight effect of Lys249 substitution on the NADPH-DCPIP reductase 
reaction remains unclear, although it could be due to the fact that the rate of this reaction is 
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limited by the enzyme oxidative half-reaction. Moreover the Lys249Ala replacement 
showed no effect on the NADH-dependent activity of PfFNR, confirming that the group of 
NADP(H) which interacts with Lys249 side chain is indeed the 2’ phosphate. As the 
whole, these results indicate that the positively charged side chain of Lys249 interacts with 
NADP(H) but it has no role in the stabilization of the HT-competent conformation of 
bound NADPH. 
In conclusion, the two basic residues Lys249 and His286 located in the adenylate-binding 
subsite of PfFNR play a significant, although not essential, role in NADP(H) binding, as 
shown also by the pH profile in the case of His286. Moreover, while Lys249 contributes to 
binding of the ground- and transition-state conformations of the substrate by interacting 
with its 2’-phosphate, His286 plays a role also in favoring the HT-competent conformation 
of NADP(H) by interacting with its pyrophosphate group. This interaction is critical in 
orienting the nicotinamide moiety of the substrate towards the flavin ring. The hydrogen 
bonding potential of the His286 side chain, rather than its possible ionic character, seems 
to be essential for this function, since the His286Gln mutation does not impair the catalytic 
properties of the enzyme, and even favors CT interactions and HT, while the His286Lys 
replacement dramatically slows turn-over. 
 Since large amounts of the purified recombinant PfFNR-C99A are required to 
support the in-depth biochemical study and the characterization of inhibitors, I 
overproduced PfFNR-C99A as cleavable fusion with SUMO protein. The global yield 
resulted 3-fold less than the recombinant PfFNR-C99A obtained without the SUMO 
fusion. The major factor limiting the accumulation of the fusion protein in E. coli is the 
partial proteolytic degradation in vivo observed for polyHis-SUMO-PfFNR-C99A. 
Nevertheless this low yield is compensated by the fact that this strategy is a fast and cheap 
lab-scale purification procedure. 
 In conclusion, the peculiar features of PfFNR highligthed by functional studies of 
mutant forms in addition to the individuation of compounds active against this enzyme, 
render PfFNR an attractive target suitable for the development of antimalarial compounds. 
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ABBREVIATIONS 
 
 
 
 
[Fe-S]    iron-sulfur cluster 
HT    hydride transfer 
Em    mid-point potential 
CT    charge transfer 
IMAC    immobilized metal ion affinity chromatography 
DTT    dithiothreitol 
PMSF    phenylmethanesulfonyl fluoride 
PVDF    polyvinylidene fluoride 
DCPIP    dichlorophenolindophenol 
FAD    flavin adenine dinucletide 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IPTG    isopropil-β-D-thiogalactopyranoside 
kcat    turnover number 
Kd    dissociation constant 
Km    Michaelis-Menten constant 
NADPH   reduced adenine dinuocleotide phosphate 
NADH   reduced nicotinamide adenine dinucleotide phosphate 
2’-P-AMP   adenosin-2’-5’-diphosphate 
EDTA    ethylenediaminetetraacetic acid 
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